DownloadHi-Res Photo

Pei Hui, PhD, MD

Professor of Pathology and of Obstetrics, Gynecology and Reproductive Sciences; Director, Gynecologic Pathology; Clinical Director, Molecular Diagnostics Laboratories; Director, Pathology

Contact Information

Pei Hui, PhD, MD

Office Location

Department of Pathology
Brady Memorial Laboratory
310 Cedar Street, Ste BML 254A
New Haven, CT 06510
Fax:203.737.4626
Appointments:203.785.6498

Yale Pathology Molecular Diagnostics Laboratory

Patient Care

Are you a patient?Please visit the Yale Medicine website for information about the services we offer and making an appointment.View Doctor Profile

Research & Publications
Biography
News
Locations

Research Summary

Dr. Hui's academic interests focus on clinical and biological aspects of gynecological cancers. Using molecular and genetic approaches, he has active research collaborations with clinical oncologists and basic science investigators in exploring the pathogenesis of common gynecological tumors including gestational trophoblastic disease, endometrial carcinomas, cervical cancers and ovarian tumors. As director of the Molecular Diagnostics Laboratory, he has been exploring molecular methods in facilitating histological evaluations of various neoplastic conditions and molecular biomarkers for therapeutic guidance and prognostication.

Specialized Terms: Gynecological tumors including endometrial, cervical and ovarian cancers; Gestational trophoblastic disease; Molecular diagnosis of cancers and molecular genotyping diagnosis of trophoblastic disease.

Coauthors

Research Interests

Adnexal Diseases; Uterine Cervical Neoplasms; Gynecology; Ovarian Neoplasms; Pathology; Uterine Neoplasms; Vaginal Neoplasms; Vulvar Neoplasms; Endometrial Neoplasms; Molecular Diagnostic Techniques; Gestational Trophoblastic Disease; Genotyping Techniques

Research Images

Pathogenesis of Hydatidiform Moles

Acquisition of global imprinting alteration at a critical time point in a preimplantation embryo occurs through the de novo absence of the maternal haploid genome in sporadic androgenetic complete hydatidiform moles (CHMs) or through mutations of NLRP7 or KHDC3L shutting down the entire maternal imprinting gene expression in familial biparental CHMs (from Annu. Rev. Pathol. Mech. Dis. 2017. 12:449–85).

Atypical Placental Site Nodule

Atypical placental site nodule (APSN). As a precursor lesion to epithelioid trophoblastic tumor, APSN has morphologic features, including larger size of greater than 5 mm (A), increased cellularity (B and C), marked nuclear atypia (C and D), increased mitotic activity (D, arrows), and increased Ki-67 proliferation index to 8%to 10% (E and F) (hematoxylin-eosin, original magnifications320 [A],3100 [B and E], and3400 [C and D]; Ki-67, original magnification3100 [F] (from Arch Pathol Lab Med. 2018 Nov 8; 2018 Nov 8. PMID: 30407075)

Minimal Microsatellite Shift in Endometrial Cancer

Microsatellite instability testing by analysis of PCR products amplified at 5 NCI recommended loci. a: Minimal microsatellite shift at four of 5 microsatellite loci (red arrows) in an endometrial endometrioid adenocarcinoma. b: Major microsatellite shifts (blue arrows) and minimal microsatellite shifts (red arrow) in a colorectal carcinoma). (From Mod Pathol. 2018 Nov 15; 2018 Nov 15. PMID: 30443012)

DNA Mismatch Repair Mechanism

DNA mismatch repair mechanism. MLH1 dimerizes with PMS2, PMS1 or MLH3 to form MutLα, MutLβ or MutLγ heterodimer, respectively. MSH2 dimerizes with MSH6 or MSH3 to form MutSα or MutSβ heterodimer respectively, with the main function of binding DNA helix and recognizing DNA mismatches. Working together with the MutL complexes, the MSH2/MSH6 (MutSα) complex guides the repair of single base mismatch and small loop mismatch, whereas the MSH2/MSH3 (MutSβ) complex guides the repair of small to large loop mismatch (Expert Review Of Molecular Diagnostics 2016, 16:591-604. 2016).

Selected Publications

KRAS mutation in primary ovarian serous borderline tumors correlates with tumor recurrenceMcHenry A, Rottmann D, Buza N, Hui P. KRAS mutation in primary ovarian serous borderline tumors correlates with tumor recurrence. Virchows Archiv 2023, 483: 71-79. PMID: 37219599, DOI: 10.1007/s00428-023-03564-z.
Corrigendum to “Elimusertib (BAY1895344), a novel ATR inhibitor, demonstrates in vivo activity in ATRX mutated models of uterine leiomyosarcoma”Harold J, Bellone S, Manavell D, Mutlu L, McNamara B, Hartwich T, Zipponi M, Yang-Hartwich Y, Demirkiran C, Verzosa M, Choi J, Dong W, Buza N, Hui P, Altwerger G, Huang G, Andikyan V, Clark M, Ratner E, Azodi M, Schwartz P, Santin A. Corrigendum to “Elimusertib (BAY1895344), a novel ATR inhibitor, demonstrates in vivo activity in ATRX mutated models of uterine leiomyosarcoma”. Gynecologic Oncology 2023, 170: 334. PMID: 36906375, PMCID: PMC10266020, DOI: 10.1016/j.ygyno.2023.01.029.
Trastuzumab deruxtecan (DS-8201a), a HER2-targeting antibody–drug conjugate with topoisomerase I inhibitor payload, shows antitumor activity in uterine and ovarian carcinosarcoma with HER2/neu expressionMauricio D, Bellone S, Mutlu L, McNamara B, Manavella D, Demirkiran C, Verzosa M, Buza N, Hui P, Hartwich T, Harold J, Yang-Hartwich Y, Zipponi M, Altwerger G, Ratner E, Huang G, Clark M, Andikyan V, Azodi M, Schwartz P, Santin A. Trastuzumab deruxtecan (DS-8201a), a HER2-targeting antibody–drug conjugate with topoisomerase I inhibitor payload, shows antitumor activity in uterine and ovarian carcinosarcoma with HER2/neu expression. Gynecologic Oncology 2023, 170: 38-45. PMID: 36610380, PMCID: PMC10445234, DOI: 10.1016/j.ygyno.2022.12.018.
Ovarian and uterine carcinosarcomas are sensitive in vitro and in vivo to elimusertib, a novel ataxia-telangiectasia and Rad3-related (ATR) kinase inhibitorManavella D, McNamara B, Harold J, Bellone S, Hartwich T, Yang-Hartwich Y, Mutlu L, Zipponi M, Demirkiran C, Verzosa M, Altwerger G, Ratner E, Huang G, Clark M, Andikyan V, Azodi M, Schwartz P, Dottino P, Choi J, Alexandrov L, Buza N, Hui P, Santin A. Ovarian and uterine carcinosarcomas are sensitive in vitro and in vivo to elimusertib, a novel ataxia-telangiectasia and Rad3-related (ATR) kinase inhibitor. Gynecologic Oncology 2022, 169: 98-105. PMID: 36525930, PMCID: PMC9925406, DOI: 10.1016/j.ygyno.2022.12.003.
Elimusertib (BAY1895344), a novel ATR inhibitor, demonstrates in vivo activity in ATRX mutated models of uterine leiomyosarcomaHarold J, Bellone S, Manavella D, Mutlu L, McNamara B, Hartwich T, Zipponi M, Yang-Hartwich Y, Demirkiran C, Verzosa M, Choi J, Dong W, Buza N, Hui P, Altwerger G, Huang G, Andikyan V, Clark M, Ratner E, Azodi M, Schwartz P, Santin A. Elimusertib (BAY1895344), a novel ATR inhibitor, demonstrates in vivo activity in ATRX mutated models of uterine leiomyosarcoma. Gynecologic Oncology 2022, 168: 157-165. PMID: 36442427, PMCID: PMC9797429, DOI: 10.1016/j.ygyno.2022.11.014.
Correlative Assessment of p53 Immunostaining Patterns and TP53 Mutation Status by Next-Generation Sequencing in High-Grade Endometrial CarcinomasMatsumoto N, Manrai P, Rottmann D, Wu X, Assem H, Hui P, Buza N. Correlative Assessment of p53 Immunostaining Patterns and TP53 Mutation Status by Next-Generation Sequencing in High-Grade Endometrial Carcinomas. International Journal Of Gynecological Pathology 2022, 42: 567-575. PMID: 36730675, DOI: 10.1097/pgp.0000000000000930.
Dataset for the Reporting of Gestational Trophoblastic Neoplasia: Recommendations From the International Collaboration on Cancer Reporting (ICCR)Hui P, Webster F, Baergen RN, Buza N, Cheung ANY, Kaur B, Ronnett BM, Shih IM, Seckl MJ, Lax SF, McCluggage WG. Dataset for the Reporting of Gestational Trophoblastic Neoplasia: Recommendations From the International Collaboration on Cancer Reporting (ICCR). International Journal Of Gynecological Pathology 2022, 41: s34-s43. PMID: 36305533, DOI: 10.1097/pgp.0000000000000876.
Intraductal papillary neoplasm of the bile duct: Cytomorphologic and molecular featuresStendahl K, Gilani SM, Basturk O, Hui P, Sigel C, Cai G. Intraductal papillary neoplasm of the bile duct: Cytomorphologic and molecular features. Cancer Cytopathology 2022, 131: 37-49. PMID: 36041224, PMCID: PMC9812877, DOI: 10.1002/cncy.22637.
Characteristics of HER2 Gene Amplification by Fluorescence In Situ Hybridization in Endometrial Serous Carcinoma.Buza N, Hui P. Characteristics of HER2 Gene Amplification by Fluorescence In Situ Hybridization in Endometrial Serous Carcinoma. Archives Of Pathology & Laboratory Medicine 2022, 146: 0. PMID: 35687792, DOI: 10.5858/arpa.2021-0547-oa.
Synergistic activity of neratinib in combination with olaparib in uterine serous carcinoma overexpressing HER2/neuYadav G, Roque DM, Bellone S, Manavella DD, Hartwich TMP, Zipponi M, Harold J, Tymon-Rosario J, Mutlu L, Altwerger G, Menderes G, Ratner E, Buza N, Hui P, Huang GS, Andikyan V, Clark M, Azodi M, Schwartz PE, Alexandrov LB, Santin AD. Synergistic activity of neratinib in combination with olaparib in uterine serous carcinoma overexpressing HER2/neu. Gynecologic Oncology 2022, 166: 351-357. PMID: 35641325, DOI: 10.1016/j.ygyno.2022.05.021.
COVID-19 & differential effects in twins: Insights from Placenta PathologyMoriarty K, Yu M, Hussain N, Zgutka K, Sanders MM, Harigopal M, Wang J, Wang X, Hui P, Liu C, Sink D, Shields A. COVID-19 & differential effects in twins: Insights from Placenta Pathology. Placenta 2022, 124: 62-66. PMID: 35640456, PMCID: PMC9121647, DOI: 10.1016/j.placenta.2022.05.014.
Combining genomic and epidemiological data to compare the transmissibility of SARS-CoV-2 variants Alpha and IotaPetrone ME, Rothman JE, Breban MI, Ott IM, Russell A, Lasek-Nesselquist E, Badr H, Kelly K, Omerza G, Renzette N, Watkins AE, Kalinich CC, Alpert T, Brito AF, Earnest R, Tikhonova IR, Castaldi C, Kelly JP, Shudt M, Plitnick J, Schneider E, Murphy S, Neal C, Laszlo E, Altajar A, Pearson C, Muyombwe A, Downing R, Razeq J, Niccolai L, Wilson MS, Anderson ML, Wang J, Liu C, Hui P, Mane S, Taylor BP, Hanage WP, Landry ML, Peaper DR, Bilguvar K, Fauver JR, Vogels CBF, Gardner LM, Pitzer VE, St. George K, Adams MD, Grubaugh ND. Combining genomic and epidemiological data to compare the transmissibility of SARS-CoV-2 variants Alpha and Iota. Communications Biology 2022, 5: 439. PMID: 35545661, PMCID: PMC9095641, DOI: 10.1038/s42003-022-03347-3.
Endometrial Polyp in Postmenopausal Women.Hui P. Endometrial Polyp in Postmenopausal Women. Archives Of Pathology & Laboratory Medicine 2022 PMID: 35512230, DOI: 10.5858/arpa.2021-0557-RA.
Significance of KRAS mutation testing in biliary brushing cytology specimens: A 10‐year retrospective reviewSun T, Zuo T, Hui P, Cai G. Significance of KRAS mutation testing in biliary brushing cytology specimens: A 10‐year retrospective review. Cancer Cytopathology 2022, 130: 558-565. PMID: 35417072, DOI: 10.1002/cncy.22579.
SaliVISION: a rapid saliva-based COVID-19 screening and diagnostic test with high sensitivity and specificityDeFina SM, Wang J, Yang L, Zhou H, Adams J, Cushing W, Tuohy B, Hui P, Liu C, Pham K. SaliVISION: a rapid saliva-based COVID-19 screening and diagnostic test with high sensitivity and specificity. Scientific Reports 2022, 12: 5729. PMID: 35388102, PMCID: PMC8986854, DOI: 10.1038/s41598-022-09718-4.
Randomised phase II trial of weekly ixabepilone ± biweekly bevacizumab for platinum-resistant or refractory ovarian/fallopian tube/primary peritoneal cancerRoque DM, Siegel ER, Buza N, Bellone S, Silasi DA, Huang GS, Andikyan V, Clark M, Azodi M, Schwartz PE, Rao GG, Reader JC, Hui P, Tymon-Rosario JR, Harold J, Mauricio D, Zeybek B, Menderes G, Altwerger G, Ratner E, Santin AD. Randomised phase II trial of weekly ixabepilone ± biweekly bevacizumab for platinum-resistant or refractory ovarian/fallopian tube/primary peritoneal cancer. British Journal Of Cancer 2022, 126: 1695-1703. PMID: 35149854, PMCID: PMC8853032, DOI: 10.1038/s41416-022-01717-6.
Clinicopathologic characteristics and oncologic outcomes in adenosarcoma of gynecologic sitesLi JY, Mutlu L, Tymon-Rosario J, Khadraoui W, Nagarkatti N, Hui P, Buza N, Lu L, Schwartz P, Menderes G. Clinicopathologic characteristics and oncologic outcomes in adenosarcoma of gynecologic sites. Gynecologic Oncology Reports 2021, 39: 100913. PMID: 35005157, PMCID: PMC8715286, DOI: 10.1016/j.gore.2021.100913.
SARS-CoV-2 expresses a microRNA-like small RNA able to selectively repress host genesPawlica P, Yario TA, White S, Wang J, Moss WN, Hui P, Vinetz JM, Steitz JA. SARS-CoV-2 expresses a microRNA-like small RNA able to selectively repress host genes. Proceedings Of The National Academy Of Sciences Of The United States Of America 2021, 118: e2116668118. PMID: 34903581, PMCID: PMC8719879, DOI: 10.1073/pnas.2116668118.
Gestational Trophoblastic NeoplasmsHui P. Gestational Trophoblastic Neoplasms. 2021, 791-820. DOI: 10.1007/978-3-030-84725-8_29.
A phase 2 evaluation of pembrolizumab for recurrent Lynch‐like versus sporadic endometrial cancers with microsatellite instabilityBellone S, Roque DM, Siegel ER, Buza N, Hui P, Bonazzoli E, Guglielmi A, Zammataro L, Nagarkatti N, Zaidi S, Lee J, Silasi D, Huang GS, Andikyan V, Damast S, Clark M, Azodi M, Schwartz PE, Tymon‐Rosario J, Harold JA, Mauricio D, Zeybek B, Menderes G, Altwerger G, Ratner E, Alexandrov LB, Iwasaki A, Kong Y, Song E, Dong W, Elvin JA, Choi J, Santin AD. A phase 2 evaluation of pembrolizumab for recurrent Lynch‐like versus sporadic endometrial cancers with microsatellite instability. Cancer 2021, 128: 1206-1218. PMID: 34875107, PMCID: PMC9465822, DOI: 10.1002/cncr.34025.
Progression of Cystadenoma to Mucinous Borderline Ovarian Tumor in Young Females: Case Series and Literature ReviewBeroukhim G, Ozgediz D, Cohen PJ, Hui P, Morotti R, Schwartz PE, Yang-Hartwich, Vash-Margita A. Progression of Cystadenoma to Mucinous Borderline Ovarian Tumor in Young Females: Case Series and Literature Review. Journal Of Pediatric And Adolescent Gynecology 2021, 35: 359-367. PMID: 34843973, DOI: 10.1016/j.jpag.2021.11.003.
A Timely Update of Immunohistochemistry and Molecular Classification in the Diagnosis and Risk Assessment of Endometrial Carcinomas.Wang M, Hui P. A Timely Update of Immunohistochemistry and Molecular Classification in the Diagnosis and Risk Assessment of Endometrial Carcinomas. Archives Of Pathology & Laboratory Medicine 2021, 145: 1367-1378. PMID: 34673912, DOI: 10.5858/arpa.2021-0098-ra.
Increased Detection of Mycobacterium tuberculosis Disease Using a Tissue-Based Laboratory-Developed Polymerase Chain Reaction Assay Compared to Standard Diagnostics.Mackow NA, Abi-Raad R, Kerantzas CA, Hui P, Malinis M, Azar MM. Increased Detection of Mycobacterium tuberculosis Disease Using a Tissue-Based Laboratory-Developed Polymerase Chain Reaction Assay Compared to Standard Diagnostics. American Journal Of Tropical Medicine And Hygiene 2021, 105: 1657-1661. PMID: 34544041, PMCID: PMC8641361, DOI: 10.4269/ajtmh.21-0104.
Minimal uterine serous carcinoma and endometrial polyp: a close clinicopathological relationshipAssem H, Rottmann D, Finkelstein A, Wang M, Ratner E, Santin AD, Buza N, Hui P. Minimal uterine serous carcinoma and endometrial polyp: a close clinicopathological relationship. Human Pathology 2021, 118: 1-8. PMID: 34508766, DOI: 10.1016/j.humpath.2021.09.001.
Immunohistochemical and molecular pathological typing in the differential diagnosis and prognosis risk assessment of endometrial carcinomaWang M, Hui P. Immunohistochemical and molecular pathological typing in the differential diagnosis and prognosis risk assessment of endometrial carcinoma. 中华病理学杂志 2021, 50: 1078-1082. PMID: 34496509, DOI: 10.3760/cma.j.cn112151-20210628-00463.
DHES0815A, a novel antibody-drug conjugate targeting HER2/neu, is highly active against uterine serous carcinomas in vitro and in vivoTymon-Rosario J, Bonazzoli E, Bellone S, Manzano A, Pelligra S, Guglielmi A, Gnutti B, Nagarkatti N, Zeybek B, Manara P, Zammataro L, Harold J, Mauricio D, Buza N, Hui P, Altwerger G, Menderes G, Ratner E, Clark M, Andikyan V, Huang GS, Silasi DA, Azodi M, Schwartz PE, Santin AD. DHES0815A, a novel antibody-drug conjugate targeting HER2/neu, is highly active against uterine serous carcinomas in vitro and in vivo. Gynecologic Oncology 2021, 163: 334-341. PMID: 34452746, PMCID: PMC8722447, DOI: 10.1016/j.ygyno.2021.08.014.
Clinicopathologic characteristics and oncologic outcomes in adenosarcoma of gynecologic sitesMutlu L, Li J, Tymon-Rosario J, Hui P, Menderes G. Clinicopathologic characteristics and oncologic outcomes in adenosarcoma of gynecologic sites. Gynecologic Oncology 2021, 162: s113-s114. DOI: 10.1016/s0090-8258(21)00857-x.
Randomized phase II trial of weekly ixabepilone with or without biweekly bevacizumab for platinum-resistant or refractory ovarian/fallopian tube/primary peritoneal cancerRoque D, Siegel E, Buza N, Bellone S, Silasi D, Huang G, Andikyan V, Clark M, Azodi M, Schwartz P, Rao G, Reader J, Hui P, Tymon-Rosario J, Harold J, Mauricio D, Zeybek B, Menderes G, Altwerger G, Ratner E, Santin A. Randomized phase II trial of weekly ixabepilone with or without biweekly bevacizumab for platinum-resistant or refractory ovarian/fallopian tube/primary peritoneal cancer. Gynecologic Oncology 2021, 162: s58. DOI: 10.1016/s0090-8258(21)00753-8.
Diseases of the Fallopian TubeXing D, Snir O, Hui P. Diseases of the Fallopian Tube. 2021, 193-223. DOI: 10.1007/978-3-030-68608-6_8.
Gestational Trophoblastic DiseasesBuza N, Hui P. Gestational Trophoblastic Diseases. 2021, 173-191. DOI: 10.1007/978-3-030-68608-6_7.
Uterine Epithelial NeoplasiaHui P, Flynn C, Quddus M. Uterine Epithelial Neoplasia. 2021, 113-130. DOI: 10.1007/978-3-030-68608-6_5.
Non-HPV-Associated Cervical NeoplasiaQuddus M, Ou J, Hui P. Non-HPV-Associated Cervical Neoplasia. 2021, 95-111. DOI: 10.1007/978-3-030-68608-6_4.
Molecular DiagnosisWeisman P, Wei J, Hui P. Molecular Diagnosis. 2021, 417-431. DOI: 10.1007/978-3-030-68608-6_16.
ImmunohistochemistryEuscher E, Buza N, Hui P. Immunohistochemistry. 2021, 367-416. DOI: 10.1007/978-3-030-68608-6_15.
Miscellaneous Neoplasia of the OvaryHui P, Banet N. Miscellaneous Neoplasia of the Ovary. 2021, 283-295. DOI: 10.1007/978-3-030-68608-6_11.
Cervical carcinomas that overexpress human trophoblast cell-surface marker (Trop-2) are highly sensitive to the antibody-drug conjugate sacituzumab-govitecanZeybek B, Manzano A, Bianchi A, Bonazzoli E, Bellone S, Buza N, Hui P, Lopez S, Perrone E, Manara P, Zammataro L, Altwerger G, Han C, Tymon-Rosario J, Menderes G, Ratner E, Silasi D, Huang G, Azodi M, Schwartz P, Santin A. Cervical carcinomas that overexpress human trophoblast cell-surface marker (Trop-2) are highly sensitive to the antibody-drug conjugate sacituzumab-govitecan. Gynecologic Oncology 2020, 159: 177. DOI: 10.1016/j.ygyno.2020.05.265.
Randomized phase II trial of carboplatin-paclitaxel compared to carboplatin-paclitaxel-trastuzumab in advanced or recurrent uterine serous carcinomas that overexpress HER2/Neu (NCT01367002): Updated survival analysisFader A, Roque D, Siegel E, Buza N, Hui P, Havrilesky L, Secord A, O'Malley D, Backes F, Nevadunsky N, Chambers S, Edraki B, Celano P, Bellone S, Azodi M, Ratner E, Litkouhi B, Silasi D, Schwartz P, Santin A. Randomized phase II trial of carboplatin-paclitaxel compared to carboplatin-paclitaxel-trastuzumab in advanced or recurrent uterine serous carcinomas that overexpress HER2/Neu (NCT01367002): Updated survival analysis. Gynecologic Oncology 2020, 159: 7-8. DOI: 10.1016/j.ygyno.2020.06.014.
Does Specimen Type Have an Impact on HER2 Status in Endometrial Serous Carcinoma? Discordant HER2 Status of Paired Endometrial Biopsy and Hysterectomy Specimens in the Presence of Frequent Intratumoral HeterogeneityRottmann D, Assem H, Matsumoto N, Wong S, Hui P, Buza N. Does Specimen Type Have an Impact on HER2 Status in Endometrial Serous Carcinoma? Discordant HER2 Status of Paired Endometrial Biopsy and Hysterectomy Specimens in the Presence of Frequent Intratumoral Heterogeneity. International Journal Of Gynecological Pathology 2020, 40: 263-271. PMID: 32897955, DOI: 10.1097/pgp.0000000000000690.
Randomized Phase II Trial of Carboplatin–Paclitaxel Compared with Carboplatin–Paclitaxel–Trastuzumab in Advanced (Stage III–IV) or Recurrent Uterine Serous Carcinomas that Overexpress Her2/Neu (NCT01367002): Updated Overall Survival AnalysisFader AN, Roque DM, Siegel E, Buza N, Hui P, Abdelghany O, Chambers S, Secord AA, Havrilesky L, O'Malley DM, Backes FJ, Nevadunsky N, Edraki B, Pikaart D, Lowery W, ElSahwi K, Celano P, Bellone S, Azodi M, Litkouhi B, Ratner E, Silasi DA, Schwartz PE, Santin AD. Randomized Phase II Trial of Carboplatin–Paclitaxel Compared with Carboplatin–Paclitaxel–Trastuzumab in Advanced (Stage III–IV) or Recurrent Uterine Serous Carcinomas that Overexpress Her2/Neu (NCT01367002): Updated Overall Survival Analysis. Clinical Cancer Research 2020, 26: 3928-3935. PMID: 32601075, PMCID: PMC8792803, DOI: 10.1158/1078-0432.ccr-20-0953.
Lack of genetic homozygosity in prepubertal teratomas: divergent pathogenesis distinct from that of teratomas in adolescentsSnir OL, DeJoseph M, Wu X, Rottmann D, Wong S, Buza N, Hui P. Lack of genetic homozygosity in prepubertal teratomas: divergent pathogenesis distinct from that of teratomas in adolescents. Laboratory Investigation 2020, 100: 1447-1454. PMID: 32694569, DOI: 10.1038/s41374-020-0468-6.
Germline NLRP7 mutations: genomic imprinting and hydatidiform moleHui P. Germline NLRP7 mutations: genomic imprinting and hydatidiform mole. Virchows Archiv 2020, 477: 175-176. PMID: 32577811, DOI: 10.1007/s00428-020-02802-y.
Genital tuberculosis screening at an academic fertility center in the United StatesTal R, Lawal T, Granger E, Simoni M, Hui P, Buza N, Pal L. Genital tuberculosis screening at an academic fertility center in the United States. American Journal Of Obstetrics And Gynecology 2020, 223: 737.e1-737.e10. PMID: 32497612, DOI: 10.1016/j.ajog.2020.05.045.
Heterozygous/dispermic complete mole confers a significantly higher risk for post-molar gestational trophoblastic diseaseZheng XZ, Qin XY, Chen SW, Wang P, Zhan Y, Zhong PP, Buza N, Jin YL, Wu BQ, Hui P. Heterozygous/dispermic complete mole confers a significantly higher risk for post-molar gestational trophoblastic disease. Modern Pathology 2020, 33: 1979-1988. PMID: 32404958, DOI: 10.1038/s41379-020-0566-4.
Extragonadal Yolk Sac Tumor Limited to the Myometrium: Report of a Case With Potential Fertility Preservation and Molecular Analysis Suggesting Germ Cell OriginSimpson S, Simoni M, Hui P, Taylor H, Buza N. Extragonadal Yolk Sac Tumor Limited to the Myometrium: Report of a Case With Potential Fertility Preservation and Molecular Analysis Suggesting Germ Cell Origin. International Journal Of Gynecological Pathology 2020, 39: 247-253. PMID: 31033797, DOI: 10.1097/pgp.0000000000000601.
Molecular and clinicopathologic characterization of intravenous leiomyomatosisOrdulu Z, Chai H, Peng G, McDonald AG, De Nictolis M, Garcia-Fernandez E, Hardisson D, Prat J, Li P, Hui P, Oliva E, Buza N. Molecular and clinicopathologic characterization of intravenous leiomyomatosis. Modern Pathology 2020, 33: 1844-1860. PMID: 32341498, PMCID: PMC7483566, DOI: 10.1038/s41379-020-0546-8.
Bilateral Signet-ring Stromal Tumor of the Ovary: A Case Report With Next-generation Sequencing Analysis and FOXL2 Mutation TestingChen PH, Hui P, Buza N. Bilateral Signet-ring Stromal Tumor of the Ovary: A Case Report With Next-generation Sequencing Analysis and FOXL2 Mutation Testing. International Journal Of Gynecological Pathology 2020, 39: 193-198. PMID: 30676431, DOI: 10.1097/pgp.0000000000000579.
Selection of HER2/NEU negative tumor cells as a mechanism of resistance to trastuzumab in uterine serous carcinomaPelligra S, Buza N, Hui P, Bellone S, Zeybek B, Ratner E, Schwartz PE, Scambia G, Santin AD. Selection of HER2/NEU negative tumor cells as a mechanism of resistance to trastuzumab in uterine serous carcinoma. Gynecologic Oncology Reports 2020, 32: 100554. PMID: 32140533, PMCID: PMC7049633, DOI: 10.1016/j.gore.2020.100554.
Preclinical Activity of Sacituzumab Govitecan, an Antibody-Drug Conjugate Targeting Trophoblast Cell-Surface Antigen 2 (Trop-2) Linked to the Active Metabolite of Irinotecan (SN-38), in Ovarian CancerPerrone E, Lopez S, Zeybek B, Bellone S, Bonazzoli E, Pelligra S, Zammataro L, Manzano A, Manara P, Bianchi A, Buza N, Tymon-Rosario J, Altwerger G, Han C, Menderes G, Ratner E, Silasi DA, Azodi M, Hui P, Schwartz PE, Scambia G, Santin AD. Preclinical Activity of Sacituzumab Govitecan, an Antibody-Drug Conjugate Targeting Trophoblast Cell-Surface Antigen 2 (Trop-2) Linked to the Active Metabolite of Irinotecan (SN-38), in Ovarian Cancer. Frontiers In Oncology 2020, 10: 118. PMID: 32117765, PMCID: PMC7028697, DOI: 10.3389/fonc.2020.00118.
Preclinical activity of sacituzumab govitecan (IMMU-132) in uterine and ovarian carcinosarcomasLopez S, Perrone E, Bellone S, Bonazzoli E, Zeybek B, Han C, Tymon-Rosario J, Altwerger G, Menderes G, Bianchi A, Zammataro L, Manzano A, Manara P, Ratner E, Silasi DA, Huang GS, Azodi M, Schwartz PE, Raspagliesi F, Angioli R, Buza N, Hui P, Bond HM, Santin AD. Preclinical activity of sacituzumab govitecan (IMMU-132) in uterine and ovarian carcinosarcomas. Oncotarget 2020, 11: 560-570. PMID: 32082489, PMCID: PMC7007291, DOI: 10.18632/oncotarget.27342.
Cervical carcinomas that overexpress human trophoblast cell-surface marker (Trop-2) are highly sensitive to the antibody-drug conjugate sacituzumab govitecanZeybek B, Manzano A, Bianchi A, Bonazzoli E, Bellone S, Buza N, Hui P, Lopez S, Perrone E, Manara P, Zammataro L, Altwerger G, Han C, Tymon-Rosario J, Menderes G, Ratner E, Silasi DA, Huang GS, Azodi M, Schwartz PE, Santin A. Cervical carcinomas that overexpress human trophoblast cell-surface marker (Trop-2) are highly sensitive to the antibody-drug conjugate sacituzumab govitecan. Scientific Reports 2020, 10: 973. PMID: 31969666, PMCID: PMC6976591, DOI: 10.1038/s41598-020-58009-3.
Sacituzumab govitecan, an antibody‐drug conjugate targeting trophoblast cell‐surface antigen 2, shows cytotoxic activity against poorly differentiated endometrial adenocarcinomas in vitro and in vivoPerrone E, Manara P, Lopez S, Bellone S, Bonazzoli E, Manzano A, Zammataro L, Bianchi A, Zeybek B, Buza N, Tymon‐Rosario J, Altwerger G, Han C, Menderes G, Huang GS, Ratner E, Silasi D, Azodi M, Hui P, Schwartz PE, Scambia G, Santin AD. Sacituzumab govitecan, an antibody‐drug conjugate targeting trophoblast cell‐surface antigen 2, shows cytotoxic activity against poorly differentiated endometrial adenocarcinomas in vitro and in vivo. Molecular Oncology 2020, 14: 645-656. PMID: 31891442, PMCID: PMC7053235, DOI: 10.1002/1878-0261.12627.
Frequent loss of mutation-specific mismatch repair protein expression in nonneoplastic endometrium of Lynch syndrome patientsWong S, Hui P, Buza N. Frequent loss of mutation-specific mismatch repair protein expression in nonneoplastic endometrium of Lynch syndrome patients. Modern Pathology 2020, 33: 1172-1181. PMID: 31932681, DOI: 10.1038/s41379-020-0455-x.
In vitro and in vivo activity of sacituzumab govitecan, an antibody-drug conjugate targeting trophoblast cell-surface antigen 2 (Trop-2) in uterine serous carcinomaHan C, Perrone E, Zeybek B, Bellone S, Tymon-Rosario J, Altwerger G, Menderes G, Feinberg J, Haines K, Muller Karger ME, Bianchi A, Zammataro L, Manzano A, Bonazzoli E, Manara P, Buza N, Hui P, Ratner E, Silasi DA, Huang GS, Azodi M, Schwartz PE, Lopez S, Santin AD. In vitro and in vivo activity of sacituzumab govitecan, an antibody-drug conjugate targeting trophoblast cell-surface antigen 2 (Trop-2) in uterine serous carcinoma. Gynecologic Oncology 2019, 156: 430-438. PMID: 31839338, DOI: 10.1016/j.ygyno.2019.11.018.
Whole-exome sequencing of cervical carcinomas identifies activating ERBB2 and PIK3CA mutations as targets for combination therapyZammataro L, Lopez S, Bellone S, Pettinella F, Bonazzoli E, Perrone E, Zhao S, Menderes G, Altwerger G, Han C, Zeybek B, Bianchi A, Manzano A, Manara P, Cocco E, Buza N, Hui P, Wong S, Ravaggi A, Bignotti E, Romani C, Todeschini P, Zanotti L, Odicino F, Pecorelli S, Donzelli C, Ardighieri L, Angioli R, Raspagliesi F, Scambia G, Choi J, Dong W, Bilguvar K, Alexandrov LB, Silasi DA, Huang GS, Ratner E, Azodi M, Schwartz PE, Pirazzoli V, Stiegler AL, Boggon TJ, Lifton RP, Schlessinger J, Santin AD. Whole-exome sequencing of cervical carcinomas identifies activating ERBB2 and PIK3CA mutations as targets for combination therapy. Proceedings Of The National Academy Of Sciences Of The United States Of America 2019, 116: 22730-22736. PMID: 31624127, PMCID: PMC6842590, DOI: 10.1073/pnas.1911385116.
HER2 testing of gynecologic carcinosarcomas: tumor stratification for potential targeted therapyRottmann D, Snir OL, Wu X, Wong S, Hui P, Santin AD, Buza N. HER2 testing of gynecologic carcinosarcomas: tumor stratification for potential targeted therapy. Modern Pathology 2019, 33: 118-127. PMID: 31477811, DOI: 10.1038/s41379-019-0358-x.
Inverted duplication, triplication and quintuplication through sequential breakage‐fusion‐bridge events induced by a terminal deletion at 5p in a case of spontaneous abortionChai H, Grommisch B, DiAdamo A, Wen J, Hui P, Li P. Inverted duplication, triplication and quintuplication through sequential breakage‐fusion‐bridge events induced by a terminal deletion at 5p in a case of spontaneous abortion. Molecular Genetics & Genomic Medicine 2019, 7: e00965. PMID: 31478360, PMCID: PMC6785443, DOI: 10.1002/mgg3.965.
Prognostic markers for immunodeficiency-associated primary central nervous system lymphomaKaulen LD, Galluzzo D, Hui P, Barbiero F, Karschnia P, Huttner A, Fulbright R, Baehring JM. Prognostic markers for immunodeficiency-associated primary central nervous system lymphoma. Journal Of Neuro-Oncology 2019, 144: 107-115. PMID: 31190317, DOI: 10.1007/s11060-019-03208-w.
Adjuvant Hormonal Therapy for Low-Grade Endometrial Stromal SarcomaDeshmukh U, Black J, Perez-Irizarry J, Passarelli R, Levy K, Rostkowski A, Hui P, Rutherford TJ, Santin AD, Azodi M, Silasi DA, Ratner E, Litkouhi B, Schwartz PE. Adjuvant Hormonal Therapy for Low-Grade Endometrial Stromal Sarcoma. Reproductive Sciences 2019, 26: 600-608. PMID: 29843577, DOI: 10.1177/1933719118778801.
Precision genotyping diagnosis of lung tumors with trophoblastic morphology in young womenBuza N, Baine I, Hui P. Precision genotyping diagnosis of lung tumors with trophoblastic morphology in young women. Modern Pathology 2019, 32: 1271-1280. PMID: 31028360, DOI: 10.1038/s41379-019-0275-z.
Paternal uniparental isodisomy of tyrosine hydroxylase locus at chromosome 11p15.4: spectrum of phenotypical presentations simulating hydatidiform molesBuza N, McGregor SM, Barroilhet L, Zheng X, Hui P. Paternal uniparental isodisomy of tyrosine hydroxylase locus at chromosome 11p15.4: spectrum of phenotypical presentations simulating hydatidiform moles. Modern Pathology 2019, 32: 1180-1188. PMID: 30952972, DOI: 10.1038/s41379-019-0266-0.
Clinical Insignficance of Monoclonal T-Cell Populations and Duodenal Intraepithelial T-Cell Phenotypes in Celiac and Nonceliac PatientsCelli R, Hui P, Triscott H, Bogardus S, Gibson J, Hwang M, Robert ME. Clinical Insignficance of Monoclonal T-Cell Populations and Duodenal Intraepithelial T-Cell Phenotypes in Celiac and Nonceliac Patients. The American Journal Of Surgical Pathology 2019, 43: 151-160. PMID: 30334829, DOI: 10.1097/pas.0000000000001172.
Practical applications of DNA genotyping in diagnostic pathologyBaine I, Hui P. Practical applications of DNA genotyping in diagnostic pathology. Expert Review Of Molecular Diagnostics 2019, 19: 175-188. PMID: 30638393, DOI: 10.1080/14737159.2019.1568874.
Ten-Year Comparison Study of Type 1 and 2 Endometrial Cancers: Risk Factors and OutcomesFeinberg J, Albright B, Black J, Lu L, Passarelli R, Gysler S, Whicker M, Altwerger G, Menderes G, Hui P, Santin AD, Azodi M, Silasi DA, Ratner ES, Litkouhi B, Schwartz PE. Ten-Year Comparison Study of Type 1 and 2 Endometrial Cancers: Risk Factors and Outcomes. Gynecologic And Obstetric Investigation 2019, 84: 290-297. PMID: 30602164, DOI: 10.1159/000493132.
Mutational landscape of primary, metastatic, and recurrent ovarian cancer reveals c-MYC gains as potential target for BET inhibitorsLi C, Bonazzoli E, Bellone S, Choi J, Dong W, Menderes G, Altwerger G, Han C, Manzano A, Bianchi A, Pettinella F, Manara P, Lopez S, Yadav G, Riccio F, Zammataro L, Zeybek B, Yang-Hartwich Y, Buza N, Hui P, Wong S, Ravaggi A, Bignotti E, Romani C, Todeschini P, Zanotti L, Zizioli V, Odicino F, Pecorelli S, Ardighieri L, Silasi DA, Litkouhi B, Ratner E, Azodi M, Huang GS, Schwartz PE, Lifton RP, Schlessinger J, Santin AD. Mutational landscape of primary, metastatic, and recurrent ovarian cancer reveals c-MYC gains as potential target for BET inhibitors. Proceedings Of The National Academy Of Sciences Of The United States Of America 2018, 116: 619-624. PMID: 30584090, PMCID: PMC6329978, DOI: 10.1073/pnas.1814027116.
Frontiers in Gynecologic Pathology.Hui P, Zhang L. Frontiers in Gynecologic Pathology. Archives Of Pathology & Laboratory Medicine 2018, 142: 1457-1458. PMID: 30500276, DOI: 10.5858/arpa.2018-0360-ED.
Minimal microsatellite shift in microsatellite instability high endometrial cancer: a significant pitfall in diagnostic interpretationWu X, Snir O, Rottmann D, Wong S, Buza N, Hui P. Minimal microsatellite shift in microsatellite instability high endometrial cancer: a significant pitfall in diagnostic interpretation. Modern Pathology 2018, 32: 650-658. PMID: 30443012, DOI: 10.1038/s41379-018-0179-3.
Gestational Trophoblastic Tumors: A Timely Review of Diagnostic PathologyHui P. Gestational Trophoblastic Tumors: A Timely Review of Diagnostic Pathology. Archives Of Pathology & Laboratory Medicine 2018, 143: 65-74. PMID: 30407075, DOI: 10.5858/arpa.2018-0234-ra.
Biomarker P16 predicts progression risk of anal low-grade squamous intraepithelial lesionsLiu Y, Blakely M, Sigel K, Thin TH, Hui P, Donovan M, Gaisa MM. Biomarker P16 predicts progression risk of anal low-grade squamous intraepithelial lesions. AIDS 2018, 32: 2309-2316. PMID: 30005024, PMCID: PMC6862769, DOI: 10.1097/qad.0000000000001957.
Inhibition of BET Bromodomain Proteins with GS-5829 and GS-626510 in Uterine Serous Carcinoma, a Biologically Aggressive Variant of Endometrial CancerBonazzoli E, Predolini F, Cocco E, Bellone S, Altwerger G, Menderes G, Zammataro L, Bianchi A, Pettinella F, Riccio F, Han C, Yadav G, Lopez S, Manzano A, Manara P, Buza N, Hui P, Wong S, Litkouhi B, Ratner E, Silasi DA, Huang GS, Azodi M, Schwartz PE, Schlessinger J, Santin AD. Inhibition of BET Bromodomain Proteins with GS-5829 and GS-626510 in Uterine Serous Carcinoma, a Biologically Aggressive Variant of Endometrial Cancer. Clinical Cancer Research 2018, 24: 4845-4853. PMID: 29941483, PMCID: PMC6168417, DOI: 10.1158/1078-0432.ccr-18-0864.
FOXL2 Mutation Analysis of Ovarian Sex Cord-Stromal TumorsBuza N, Wong S, Hui P. FOXL2 Mutation Analysis of Ovarian Sex Cord-Stromal Tumors. International Journal Of Gynecological Pathology 2018, 37: 305-315. PMID: 28700438, DOI: 10.1097/pgp.0000000000000426.
Hormonal therapy for low-grade endometrial stromal sarcomaDeshmukh U, Black J, Irizarry J, Passarelli R, Levy K, Rostkowski A, Hui P, Schwartz P. Hormonal therapy for low-grade endometrial stromal sarcoma. Gynecologic Oncology 2018, 149: 196. DOI: 10.1016/j.ygyno.2018.04.446.
Remarkable in vitro and in vivo activity of IMGN853, an antibody-drug conjugate targeting folate receptor alpha linked to the tubulin-disrupting maytansinoid DM4, in biologically aggressive (type II) endometrial cancersAltwerger G, Bonazzoli E, Bellone S, Takata T, Menderes G, Pettinella F, Bianchi A, Riccio F, Feinberg J, Zammataro L, Han C, Yadav G, Dugan K, Morneault A, Ponte J, Buza N, Hui P, Litkouhi B, Ratner E, Silasi D, Huang G, Azodi M, Schwartz P, Santin A. Remarkable in vitro and in vivo activity of IMGN853, an antibody-drug conjugate targeting folate receptor alpha linked to the tubulin-disrupting maytansinoid DM4, in biologically aggressive (type II) endometrial cancers. Gynecologic Oncology 2018, 149: 70. DOI: 10.1016/j.ygyno.2018.04.159.
Data Set for the Reporting of Carcinomas of the CervixMcCluggage WG, Judge MJ, Alvarado-Cabrero I, Duggan MA, Horn LC, Hui P, Ordi J, Otis CN, Park KJ, Plante M, Stewart CJR, Wiredu EK, Rous B, Hirschowitz L. Data Set for the Reporting of Carcinomas of the Cervix. International Journal Of Gynecological Pathology 2018, 37: 205-228. PMID: 28700433, DOI: 10.1097/pgp.0000000000000412.
In vitro and in vivo activity of IMGN853, an Antibody-Drug Conjugate targeting Folate Receptor Alpha linked to DM4, in biologically aggressive endometrial cancersAltwerger G, Bonazzoli E, Bellone S, Egawa-Takata T, Menderes G, Pettinella F, Bianchi A, Riccio F, Feinberg J, Zammataro L, Han C, Yadav G, Dugan K, Morneault A, Ponte JF, Buza N, Hui P, Wong S, Litkouhi B, Ratner E, Silasi DA, Huang GS, Azodi M, Schwartz PE, Santin AD. In vitro and in vivo activity of IMGN853, an Antibody-Drug Conjugate targeting Folate Receptor Alpha linked to DM4, in biologically aggressive endometrial cancers. Molecular Cancer Therapeutics 2018, 17: molcanther.0930.2017. PMID: 29440294, PMCID: PMC5932245, DOI: 10.1158/1535-7163.mct-17-0930.
Randomized Phase II Trial of Carboplatin-Paclitaxel Versus Carboplatin-Paclitaxel-Trastuzumab in Uterine Serous Carcinomas That Overexpress Human Epidermal Growth Factor Receptor 2/neu.Fader AN, Roque DM, Siegel E, Buza N, Hui P, Abdelghany O, Chambers SK, Secord AA, Havrilesky L, O'Malley DM, Backes F, Nevadunsky N, Edraki B, Pikaart D, Lowery W, ElSahwi KS, Celano P, Bellone S, Azodi M, Litkouhi B, Ratner E, Silasi DA, Schwartz PE, Santin AD. Randomized Phase II Trial of Carboplatin-Paclitaxel Versus Carboplatin-Paclitaxel-Trastuzumab in Uterine Serous Carcinomas That Overexpress Human Epidermal Growth Factor Receptor 2/neu. Journal Of Clinical Oncology 2018, 36: 2044-2051. PMID: 29584549, DOI: 10.1200/jco.2017.76.5966.
MicroRNA signatures discriminate between uterine and ovarian serous carcinomasHui P, Gysler SM, Uduman M, Togun TA, Prado DE, Brambs CE, Nallur S, Schwartz PE, Rutherford TJ, Santin AD, Weidhaas JB, Ratner ES. MicroRNA signatures discriminate between uterine and ovarian serous carcinomas. Human Pathology 2018, 76: 133-140. PMID: 29518404, DOI: 10.1016/j.humpath.2018.02.019.
Associated characteristics and impact on recurrence and survival of free-floating tumor fragments in the lumen of fallopian tubes in Type I and Type II endometrial cancerAlbright BB, Black JD, Passarelli R, Gysler S, Whicker M, Altwerger G, Menderes G, Buza N, Hui P, Santin AD, Azodi M, Silasi DA, Ratner ES, Litkouhi B, Schwartz PE. Associated characteristics and impact on recurrence and survival of free-floating tumor fragments in the lumen of fallopian tubes in Type I and Type II endometrial cancer. Gynecologic Oncology Reports 2018, 23: 28-33. PMID: 29387776, PMCID: PMC5771964, DOI: 10.1016/j.gore.2018.01.003.
Hormone producing gynecological tumors: pathologic entities and clinical significanceBoto AN, Hui P. Hormone producing gynecological tumors: pathologic entities and clinical significance. Expert Review Of Endocrinology & Metabolism 2017, 13: 9-24. PMID: 30063444, DOI: 10.1080/17446651.2018.1411799.
RARE-05. PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA IN IMMUNOCOMPROMISED HOSTS – A SINGLE INSTITUTION RETROSPECTIVE STUDY (2002-2017)Kaulen L, Galluzzo D, Hui P, Huttner A, Fulbright R, Baehring J. RARE-05. PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA IN IMMUNOCOMPROMISED HOSTS – A SINGLE INSTITUTION RETROSPECTIVE STUDY (2002-2017). Neuro-Oncology 2017, 19: vi212-vi212. PMCID: PMC5692004, DOI: 10.1093/neuonc/nox168.858.
Low-Grade Astrocytoma within a Mature Cystic Teratoma in an Adolescent PatientYoder N, Marks A, Hui P, Litkouhi B, Cron J. Low-Grade Astrocytoma within a Mature Cystic Teratoma in an Adolescent Patient. Journal Of Pediatric And Adolescent Gynecology 2017, 31: 325-327. PMID: 29107097, DOI: 10.1016/j.jpag.2017.10.005.
KRAS mutation of extraovarian implants of serous borderline tumor: prognostic indicator for adverse clinical outcomeZuo T, Wong S, Buza N, Hui P. KRAS mutation of extraovarian implants of serous borderline tumor: prognostic indicator for adverse clinical outcome. Modern Pathology 2017, 31: 350-357. PMID: 29027536, DOI: 10.1038/modpathol.2017.121.
SYD985, a Novel Duocarmycin-Based HER2-Targeting Antibody–Drug Conjugate, Shows Antitumor Activity in Uterine and Ovarian Carcinosarcoma with HER2/Neu ExpressionMenderes G, Bonazzoli E, Bellone S, Black J, Predolini F, Pettinella F, Masserdotti A, Zammataro L, Altwerger G, Buza N, Hui P, Wong S, Litkouhi B, Ratner E, Silasi DA, Azodi M, Schwartz PE, Santin AD. SYD985, a Novel Duocarmycin-Based HER2-Targeting Antibody–Drug Conjugate, Shows Antitumor Activity in Uterine and Ovarian Carcinosarcoma with HER2/Neu Expression. Clinical Cancer Research 2017, 23: 5836-5845. PMID: 28679774, PMCID: PMC5626613, DOI: 10.1158/1078-0432.ccr-16-2862.
Immunohistochemistry in Gynecologic Pathology: An Example-Based Practical UpdateBuza N, Hui P. Immunohistochemistry in Gynecologic Pathology: An Example-Based Practical Update. Archives Of Pathology & Laboratory Medicine 2017, 141: 1052-1071. PMID: 28745567, DOI: 10.5858/arpa.2016-0541-ra.
Superior in vitro and in vivo activity of trastuzumab-emtansine (T-DM1) in comparison to trastuzumab, pertuzumab and their combination in epithelial ovarian carcinoma with high HER2/neu expressionMenderes G, Bonazzoli E, Bellone S, Altwerger G, Black JD, Dugan K, Pettinella F, Masserdotti A, Riccio F, Bianchi A, Zammataro L, de Haydu C, Buza N, Hui P, Wong S, Huang GS, Litkouhi B, Ratner E, Silasi DA, Azodi M, Schwartz PE, Santin AD. Superior in vitro and in vivo activity of trastuzumab-emtansine (T-DM1) in comparison to trastuzumab, pertuzumab and their combination in epithelial ovarian carcinoma with high HER2/neu expression. Gynecologic Oncology 2017, 147: 145-152. PMID: 28705408, PMCID: PMC5605415, DOI: 10.1016/j.ygyno.2017.07.009.
Abstract 47: SYD985, a novel duocarmycin-based HER2-targeting antibody-drug conjugate, shows antitumor activity in uterine and ovarian carcinosarcoma with HER2/neu expressionMenderes G, Bonazzoli E, Bellone S, Black J, Altwerger G, Masserdotti A, Pettinella F, Zammataro L, Buza N, Hui P, Ratner E, Litkouhi B, Silasi D, Azodi M, Schwartz P, Santin A. Abstract 47: SYD985, a novel duocarmycin-based HER2-targeting antibody-drug conjugate, shows antitumor activity in uterine and ovarian carcinosarcoma with HER2/neu expression. Cancer Research 2017, 77: 47-47. DOI: 10.1158/1538-7445.am2017-47.
Ancillary studies for precision diagnosis of hydatidiform molesBuza N, Hui P. Ancillary studies for precision diagnosis of hydatidiform moles. Diagnostic Histopathology 2017, 23: 292-302. DOI: 10.1016/j.mpdhp.2017.05.003.
Frequent homozygosity in both mature and immature ovarian teratomas: a shared genetic basis of tumorigenesisSnir OL, DeJoseph M, Wong S, Buza N, Hui P. Frequent homozygosity in both mature and immature ovarian teratomas: a shared genetic basis of tumorigenesis. Modern Pathology 2017, 30: 1467-1475. PMID: 28664933, DOI: 10.1038/modpathol.2017.66.
SYD985, a novel duocarmycin-based HER2-targeting antibody-drug conjugate, shows promising antitumor activity in epithelial ovarian carcinoma with HER2/neu expression.Menderes G, Bonazzoli E, Bellone S, Black J, Altwerger G, Pettinella F, Masserdotti A, Zammataro L, Buza N, Hui P, Wong S, Litkouhi B, Ratner E, Silasi D, Azodi M, Schwartz P, Santin A. SYD985, a novel duocarmycin-based HER2-targeting antibody-drug conjugate, shows promising antitumor activity in epithelial ovarian carcinoma with HER2/neu expression. Journal Of Clinical Oncology 2017, 35: e14009-e14009. DOI: 10.1200/jco.2017.35.15_suppl.e14009.
SYD985, a novel duocarmycin-based HER2-targeting antibody-drug conjugate, shows promising antitumor activity in epithelial ovarian carcinoma with HER2/Neu expressionMenderes G, Bonazzoli E, Bellone S, Black J, Altwerger G, Masserdotti A, Pettinella F, Zammataro L, Buza N, Hui P, Wong S, Litkouhi B, Ratner E, Silasi DA, Huang GS, Azodi M, Schwartz PE, Santin AD. SYD985, a novel duocarmycin-based HER2-targeting antibody-drug conjugate, shows promising antitumor activity in epithelial ovarian carcinoma with HER2/Neu expression. Gynecologic Oncology 2017, 146: 179-186. PMID: 28473206, PMCID: PMC5533304, DOI: 10.1016/j.ygyno.2017.04.023.
Low-Grade Astrocytoma Within a Mature Cystic Teratoma in an Adolescent Patient: A Case ReportYoder N, Marks A, Hui P, Litkouhi B, Cron J. Low-Grade Astrocytoma Within a Mature Cystic Teratoma in an Adolescent Patient: A Case Report. Journal Of Pediatric And Adolescent Gynecology 2017, 30: 295. DOI: 10.1016/j.jpag.2017.03.059.
Isolated port site recurrence of node-negative clinical stage IB1 cervical adenocarcinomaDeshmukh U, McAdow M, Black J, Hui P, Azodi M. Isolated port site recurrence of node-negative clinical stage IB1 cervical adenocarcinoma. Gynecologic Oncology Reports 2017, 20: 54-57. PMID: 28331901, PMCID: PMC5348602, DOI: 10.1016/j.gore.2017.03.001.
Comprehensive Analysis of PAX8 Expression in Epithelial Malignancies of the Uterine CervixWong S, Hong W, Hui P, Buza N. Comprehensive Analysis of PAX8 Expression in Epithelial Malignancies of the Uterine Cervix. International Journal Of Gynecological Pathology 2017, 36: 101-106. PMID: 27362905, DOI: 10.1097/pgp.0000000000000309.
Pathologic Characteristics, Natural History, and Prognostic Implications of BRAFV600E Mutation in Pediatric Papillary Thyroid CarcinomaHardee S, Prasad ML, Hui P, Dinauer CA, Morotti RA. Pathologic Characteristics, Natural History, and Prognostic Implications of BRAFV600E Mutation in Pediatric Papillary Thyroid Carcinoma. Pediatric And Developmental Pathology 2017, 20: 206-212. PMID: 28521635, DOI: 10.1177/1093526616689628.
Hydatidiform Moles: Genetic Basis and Precision DiagnosisHui P, Buza N, Murphy KM, Ronnett BM. Hydatidiform Moles: Genetic Basis and Precision Diagnosis. Annual Review Of Pathology Mechanisms Of Disease 2017, 12: 449-485. PMID: 28135560, DOI: 10.1146/annurev-pathol-052016-100237.
Tissue-based chimerism analysis enhances detection of donor-derived neoplasia in allogeneic stem cell transplant patientsBaraban E, Hu S, Hui P, Podoltsev N, Cooper D, Xu M. Tissue-based chimerism analysis enhances detection of donor-derived neoplasia in allogeneic stem cell transplant patients. Bone Marrow Transplantation 2016, 52: 634-637. PMID: 27991892, DOI: 10.1038/bmt.2016.332.
Polymerase ε (POLE) ultra-mutation in uterine tumors correlates with T lymphocyte infiltration and increased resistance to platinum-based chemotherapy in vitroBellone S, Bignotti E, Lonardi S, Ferrari F, Centritto F, Masserdotti A, Pettinella F, Black J, Menderes G, Altwerger G, Hui P, Lopez S, de Haydu C, Bonazzoli E, Predolini F, Zammataro L, Cocco E, Ferrari F, Ravaggi A, Romani C, Facchetti F, Sartori E, Odicino FE, Silasi DA, Litkouhi B, Ratner E, Azodi M, Schwartz PE, Santin AD. Polymerase ε (POLE) ultra-mutation in uterine tumors correlates with T lymphocyte infiltration and increased resistance to platinum-based chemotherapy in vitro. Gynecologic Oncology 2016, 144: 146-152. PMID: 27894751, PMCID: PMC5183545, DOI: 10.1016/j.ygyno.2016.11.023.
Mutational landscape of uterine and ovarian carcinosarcomas implicates histone genes in epithelial–mesenchymal transitionZhao S, Bellone S, Lopez S, Thakral D, Schwab C, English DP, Black J, Cocco E, Choi J, Zammataro L, Predolini F, Bonazzoli E, Bi M, Buza N, Hui P, Wong S, Abu-Khalaf M, Ravaggi A, Bignotti E, Bandiera E, Romani C, Todeschini P, Tassi R, Zanotti L, Odicino F, Pecorelli S, Donzelli C, Ardighieri L, Facchetti F, Falchetti M, Silasi DA, Ratner E, Azodi M, Schwartz PE, Mane S, Angioli R, Terranova C, Quick CM, Edraki B, Bilgüvar K, Lee M, Choi M, Stiegler AL, Boggon TJ, Schlessinger J, Lifton RP, Santin AD. Mutational landscape of uterine and ovarian carcinosarcomas implicates histone genes in epithelial–mesenchymal transition. Proceedings Of The National Academy Of Sciences Of The United States Of America 2016, 113: 12238-12243. PMID: 27791010, PMCID: PMC5087050, DOI: 10.1073/pnas.1614120113.
SYD985, a Novel Duocarmycin-Based HER2-Targeting Antibody–Drug Conjugate, Shows Antitumor Activity in Uterine Serous Carcinoma with HER2/Neu ExpressionBlack J, Menderes G, Bellone S, Schwab CL, Bonazzoli E, Ferrari F, Predolini F, De Haydu C, Cocco E, Buza N, Hui P, Wong S, Lopez S, Ratner E, Silasi DA, Azodi M, Litkouhi B, Schwartz PE, Goedings P, Beusker PH, van der Lee MM, Timmers CM, Dokter WH, Santin AD. SYD985, a Novel Duocarmycin-Based HER2-Targeting Antibody–Drug Conjugate, Shows Antitumor Activity in Uterine Serous Carcinoma with HER2/Neu Expression. Molecular Cancer Therapeutics 2016, 15: 1900-1909. PMID: 27256376, DOI: 10.1158/1535-7163.mct-16-0163.
Dual CCNE1/PIK3CA targeting is synergistic in CCNE1-amplified/PIK3CA-mutated uterine serous carcinomas in vitro and in vivoCocco E, Lopez S, Black J, Bellone S, Bonazzoli E, Predolini F, Ferrari F, Schwab CL, Menderes G, Zammataro L, Buza N, Hui P, Wong S, Zhao S, Bai Y, Rimm DL, Ratner E, Litkouhi B, Silasi DA, Azodi M, Schwartz PE, Santin AD. Dual CCNE1/PIK3CA targeting is synergistic in CCNE1-amplified/PIK3CA-mutated uterine serous carcinomas in vitro and in vivo. British Journal Of Cancer 2016, 115: 303-311. PMID: 27351214, PMCID: PMC4973158, DOI: 10.1038/bjc.2016.198.
Mucinous epithelial tumours arising from ovarian mature teratomas: a tissue genotyping studySnir OL, Buza N, Hui P. Mucinous epithelial tumours arising from ovarian mature teratomas: a tissue genotyping study. Histopathology 2016, 69: 383-392. PMID: 26952875, DOI: 10.1111/his.12959.
Mismatch repair deficiency testing in clinical practiceBuza N, Ziai J, Hui P. Mismatch repair deficiency testing in clinical practice. Expert Review Of Molecular Diagnostics 2016, 16: 591-604. PMID: 26895074, DOI: 10.1586/14737159.2016.1156533.
A Comparison of the Roche Cobas HPV Test With the Hybrid Capture 2 Test for the Detection of High-Risk Human Papillomavirus GenotypesLevi AW, Bernstein JI, Hui P, Duch K, Schofield K, Chhieng DC. A Comparison of the Roche Cobas HPV Test With the Hybrid Capture 2 Test for the Detection of High-Risk Human Papillomavirus Genotypes. Archives Of Pathology & Laboratory Medicine 2016, 140: 153-7. PMID: 26910220, DOI: 10.5858/arpa.2015-0027-oa.
Putative Precursor Lesions of Gestational Trophoblastic NeoplasiaBuza N, Hui P. Putative Precursor Lesions of Gestational Trophoblastic Neoplasia. 2016, 85-102. DOI: 10.1007/978-3-319-22509-8_5.
Sarcomas and Related Mesenchymal TumorsTallini G, de Biase D, Hui P. Sarcomas and Related Mesenchymal Tumors. 2016, 487-506. DOI: 10.1007/978-3-319-19674-9_37.
Review of Leiomyoma Variants.Arleo EK, Schwartz PE, Hui P, McCarthy S. Review of Leiomyoma Variants. American Journal Of Roentgenology 2015, 205: 912-21. PMID: 26397344, DOI: 10.2214/ajr.14.13946.
Congenital nevi versus metastatic melanoma in a newborn to a mother with malignant melanoma – diagnosis supported by sex chromosome analysis and Imaging Mass SpectrometryAlomari AK, Glusac EJ, Choi J, Hui P, Seeley EH, Caprioli RM, Watsky KL, Urban J, Lazova R. Congenital nevi versus metastatic melanoma in a newborn to a mother with malignant melanoma – diagnosis supported by sex chromosome analysis and Imaging Mass Spectrometry. Journal Of Cutaneous Pathology 2015, 42: 757-764. PMID: 25989266, DOI: 10.1111/cup.12523.
Grading of atypia in genital skin lesions: routine microscopic evaluation and use of p16 immunostainingEzaldein H, Lott JP, McNiff JM, Hui P, Buza N, Ko CJ. Grading of atypia in genital skin lesions: routine microscopic evaluation and use of p16 immunostaining. Journal Of Cutaneous Pathology 2015, 42: 519-526. PMID: 25951050, DOI: 10.1111/cup.12525.
Heterozygous bone marrow in a homozygous mature ovarian teratoma: a challenge to the germ cell theory or incidental somatic heterotopia?Munday WR, Hui P. Heterozygous bone marrow in a homozygous mature ovarian teratoma: a challenge to the germ cell theory or incidental somatic heterotopia? Journal Of Clinical Pathology 2015, 68: 666. PMID: 25979987, DOI: 10.1136/jclinpath-2015-202959.
Diagnostic application of KRAS mutation testing in uterine microglandular proliferationsHong W, Abi-Raad R, Alomari AK, Hui P, Buza N. Diagnostic application of KRAS mutation testing in uterine microglandular proliferations. Human Pathology 2015, 46: 1000-1005. PMID: 25997988, DOI: 10.1016/j.humpath.2015.03.010.
Intravenous Leiomyomatosis RevisitedCarr RJ, Hui P, Buza N. Intravenous Leiomyomatosis Revisited. International Journal Of Gynecological Pathology 2015, 34: 169-176. PMID: 25675187, DOI: 10.1097/pgp.0000000000000127.
Endoscopic ultrasound-guided fine-needle aspiration biopsy of autoimmune pancreatitis: diagnostic clues and pitfallsCai G, Bernstein J, Aslanian HR, Hui P, Chhieng D. Endoscopic ultrasound-guided fine-needle aspiration biopsy of autoimmune pancreatitis: diagnostic clues and pitfalls. Journal Of The American Society Of Cytopathology 2015, 4: 211-217. PMID: 31051756, DOI: 10.1016/j.jasc.2015.01.006.
Craniopharyngioma arising in a Rathke's cleft cyst: case report.Alomari AK, Kelley BJ, Damisah E, Marks A, Hui P, DiLuna M, Vortmeyer A. Craniopharyngioma arising in a Rathke's cleft cyst: case report. Journal Of Neurosurgery Pediatrics 2015, 15: 250-4. PMID: 25555112, DOI: 10.3171/2014.11.peds14370.
Atlas of Intraoperative Frozen Section Diagnosis in Gynecologic PathologyHui P, Buza N. Atlas of Intraoperative Frozen Section Diagnosis in Gynecologic Pathology. 2015 DOI: 10.1007/978-3-319-21807-6.
[Ancillary techniques in refining the diagnosis of hydatidiform mole].Zheng X, Wu B, Buza N, Hui P. [Ancillary techniques in refining the diagnosis of hydatidiform mole]. 中华病理学杂志 2015, 44: 15-20. PMID: 25765025.
KRAS mutation testing in clinical practicePerincheri S, Hui P. KRAS mutation testing in clinical practice. Expert Review Of Molecular Diagnostics 2014, 15: 375-384. PMID: 25487540, DOI: 10.1586/14737159.2015.986102.
T-DM1, a novel antibody-drug conjugate, is highly effective against uterine and ovarian carcinosarcomas overexpressing HER2Nicoletti R, Lopez S, Bellone S, Cocco E, Schwab CL, Black JD, Centritto F, Zhu L, Bonazzoli E, Buza N, Hui P, Mezzanzanica D, Canevari S, Schwartz PE, Rutherford TJ, Santin AD. T-DM1, a novel antibody-drug conjugate, is highly effective against uterine and ovarian carcinosarcomas overexpressing HER2. Clinical & Experimental Metastasis 2014, 32: 29-38. PMID: 25398397, PMCID: PMC4310789, DOI: 10.1007/s10585-014-9688-8.
Institutional Review of Primary Non-Hodgkin Lymphoma of the Female Genital TractAhmad AK, Hui P, Litkouhi B, Azodi M, Rutherford T, McCarthy S, Xu ML, Schwartz PE, Ratner E. Institutional Review of Primary Non-Hodgkin Lymphoma of the Female Genital Tract. International Journal Of Gynecological Cancer 2014, 24: 1250-1255. PMID: 25010039, PMCID: PMC8139417, DOI: 10.1097/igc.0000000000000201.
Egg Donor PregnancyBuza N, Hui P. Egg Donor Pregnancy. International Journal Of Gynecological Pathology 2014, 33: 507-510. PMID: 25083967, DOI: 10.1097/pgp.0b013e3182a1028b.
Mitotically Active Microglandular Hyperplasia of the CervixAbi-Raad R, Alomari A, Hui P, Buza N. Mitotically Active Microglandular Hyperplasia of the Cervix. International Journal Of Gynecological Pathology 2014, 33: 524-530. PMID: 25083971, DOI: 10.1097/pgp.0000000000000086.
Best practice of BRAF V600E mutation testing for the diagnosis and management of thyroid cancersAdeniran AJ, Hui P. Best practice of BRAF V600E mutation testing for the diagnosis and management of thyroid cancers. Expert Review Of Endocrinology & Metabolism 2014, 9: 571-577. PMID: 30736195, DOI: 10.1586/17446651.2014.951635.
STR DNA genotyping of hydatidiform moles in South China.Zheng XZ, Hui P, Chang B, Gao ZB, Li Y, Wu BQ, Zhang B. STR DNA genotyping of hydatidiform moles in South China. International Journal Of Clinical And Experimental Pathology 2014, 7: 4704-19. PMID: 25197342, PMCID: PMC4152032.
Recurrent chromosomal aberrations in intravenous leiomyomatosis of the uterus: high-resolution array comparative genomic hybridization studyBuza N, Xu F, Wu W, Carr RJ, Li P, Hui P. Recurrent chromosomal aberrations in intravenous leiomyomatosis of the uterus: high-resolution array comparative genomic hybridization study. Human Pathology 2014, 45: 1885-1892. PMID: 25033729, DOI: 10.1016/j.humpath.2014.05.010.
T‐DM1, a novel antibody–drug conjugate, is highly effective against primary HER2 overexpressing uterine serous carcinoma in vitro and in vivoEnglish DP, Bellone S, Schwab CL, Bortolomai I, Bonazzoli E, Cocco E, Buza N, Hui P, Lopez S, Ratner E, Silasi D, Azodi M, Schwartz PE, Rutherford TJ, Santin AD. T‐DM1, a novel antibody–drug conjugate, is highly effective against primary HER2 overexpressing uterine serous carcinoma in vitro and in vivo. Cancer Medicine 2014, 3: 1256-1265. PMID: 24890382, PMCID: PMC4302675, DOI: 10.1002/cam4.274.
Immunohistochemistry and other ancillary techniques in the diagnosis of gestational trophoblastic diseasesBuza N, Hui P. Immunohistochemistry and other ancillary techniques in the diagnosis of gestational trophoblastic diseases. Seminars In Diagnostic Pathology 2014, 31: 223-232. PMID: 24907943, DOI: 10.1053/j.semdp.2014.03.004.
Hormonal Therapy for Aggressive AngiomyxomaSchwartz PE, Hui P, McCarthy S. Hormonal Therapy for Aggressive Angiomyxoma. Journal Of Lower Genital Tract Disease 2014, 18: e55-e61. PMID: 24402356, DOI: 10.1097/lgt.0b013e3182a22019.
Genotyping Diagnosis of Nongestational Choriocarcinoma Involving Fallopian Tube and Broad LigamentBuza N, Rutherford T, Hui P. Genotyping Diagnosis of Nongestational Choriocarcinoma Involving Fallopian Tube and Broad Ligament. International Journal Of Gynecological Pathology 2014, 33: 58-63. PMID: 24300537, DOI: 10.1097/pgp.0b013e31827cd386.
Ancillary Techniques to Refine Diagnosis of GTDBuza N, Hui P. Ancillary Techniques to Refine Diagnosis of GTD. Current Obstetrics And Gynecology Reports 2013, 3: 65-75. DOI: 10.1007/s13669-013-0072-5.
Frequent KRAS mutation in complex mucinous epithelial lesions of the endometriumAlomari A, Abi-Raad R, Buza N, Hui P. Frequent KRAS mutation in complex mucinous epithelial lesions of the endometrium. Modern Pathology 2013, 27: 675-680. PMID: 24186144, DOI: 10.1038/modpathol.2013.186.
Tissue identity testing of cancer by short tandem repeat polymorphism: pitfalls of interpretation in the presence of microsatellite instabilityMuch M, Buza N, Hui P. Tissue identity testing of cancer by short tandem repeat polymorphism: pitfalls of interpretation in the presence of microsatellite instability. Human Pathology 2013, 45: 549-555. PMID: 24444463, DOI: 10.1016/j.humpath.2013.10.022.
A Retrospective Population-Based Comparison of HER2 Immunohistochemistry and Fluorescence In Situ Hybridization in Breast Carcinomas: Impact of 2007 American Society of Clinical Oncology/ College of American Pathologists CriteriaSchalper KA, Kumar S, Hui P, Rimm DL, Gershkovich P. A Retrospective Population-Based Comparison of HER2 Immunohistochemistry and Fluorescence In Situ Hybridization in Breast Carcinomas: Impact of 2007 American Society of Clinical Oncology/ College of American Pathologists Criteria. Archives Of Pathology & Laboratory Medicine 2013, 138: 213-9. PMID: 24164555, DOI: 10.5858/arpa.2012-0617-oa.
Marked heterogeneity of HER2/NEU gene amplification in endometrial serous carcinomaBuza N, Hui P. Marked heterogeneity of HER2/NEU gene amplification in endometrial serous carcinoma. Genes Chromosomes And Cancer 2013, 52: 1178-1186. PMID: 24123408, DOI: 10.1002/gcc.22113.
Tall Cell Variant of Papillary Thyroid Microcarcinoma: Clinicopathologic Features with BRAFV600E Mutational AnalysisBernstein J, Virk RK, Hui P, Prasad A, Westra WH, Tallini G, Adeniran AJ, Udelsman R, Sasaki CT, Roman SA, Sosa JA, Prasad ML. Tall Cell Variant of Papillary Thyroid Microcarcinoma: Clinicopathologic Features with BRAFV600E Mutational Analysis. Thyroid 2013, 23: 1525-1531. PMID: 23682579, DOI: 10.1089/thy.2013.0154.
Screening for EGFR and KRAS mutations in non-small cell lung carcinomas using DNA extraction by hydrothermal pressure coupled with PCR-based direct sequencing.Liu Y, Wu BQ, Zhong HH, Hui P, Fang WG. Screening for EGFR and KRAS mutations in non-small cell lung carcinomas using DNA extraction by hydrothermal pressure coupled with PCR-based direct sequencing. International Journal Of Clinical And Experimental Pathology 2013, 6: 1880-9. PMID: 24040454, PMCID: PMC3759496.
Chromosome 17 polysomy: correlation with histological parameters and HER2NEU gene amplificationOrsaria M, Khelifa S, Buza N, Kamath A, Hui P. Chromosome 17 polysomy: correlation with histological parameters and HER2NEU gene amplification. Journal Of Clinical Pathology 2013, 66: 1070. PMID: 23908451, DOI: 10.1136/jclinpath-2013-201506.
Institutional review of primary lymphoma of the female genital tract: A 32-year experienceAhmad A, Varughese J, Hui P, Santin A, Azodi M, Silasi D, Schwartz P, Rutherford T, Ratner E. Institutional review of primary lymphoma of the female genital tract: A 32-year experience. Gynecologic Oncology 2013, 130: e152-e153. DOI: 10.1016/j.ygyno.2013.04.428.
Ovarian versus uterine serous carcinomas: Clinicopathologic and miRNA analysisAhmad A, Ahmad S, Weidhaas J, Hui P, Santin A, Azodi M, Silasi D, Schwartz P, Rutherford T, Ratner E. Ovarian versus uterine serous carcinomas: Clinicopathologic and miRNA analysis. Gynecologic Oncology 2013, 130: e92. DOI: 10.1016/j.ygyno.2013.04.274.
KRAS Mutations are Associated With Specific Morphologic Features in Colon CancerGunal A, Hui P, Kilic S, Xu R, Jain D, Mitchell K, Robert M, Kenney B. KRAS Mutations are Associated With Specific Morphologic Features in Colon Cancer. Journal Of Clinical Gastroenterology 2013, 47: 509-514. PMID: 23090042, DOI: 10.1097/mcg.0b013e3182703030.
Toward standard HER2 testing of endometrial serous carcinoma: 4-year experience at a large academic center and recommendations for clinical practiceBuza N, English DP, Santin AD, Hui P. Toward standard HER2 testing of endometrial serous carcinoma: 4-year experience at a large academic center and recommendations for clinical practice. Modern Pathology 2013, 26: 1605-1612. PMID: 23765245, DOI: 10.1038/modpathol.2013.113.
[Diagnosis, histopathologic grading and prognostic moleculer marker analysis in patients with pancreatic neuroendocrine neoplasm].Bao F, Chen GR, Hui P, Cai GP. [Diagnosis, histopathologic grading and prognostic moleculer marker analysis in patients with pancreatic neuroendocrine neoplasm]. Zhonghua Bing Li Xue Za Zhi Chinese Journal Of Pathology 2013, 42: 426-32. PMID: 24060085, DOI: 10.3760/cma.j.issn.0529-5807.2013.06.016.
Partial Hydatidiform MoleBuza N, Hui P. Partial Hydatidiform Mole. International Journal Of Gynecological Pathology 2013, 32: 307-315. PMID: 23518914, DOI: 10.1097/pgp.0b013e3182626011.
High Frequency of Putative Ovarian Cancer Stem Cells With CD44/CK19 Coexpression Is Associated With Decreased Progression-Free Intervals In Patients With Recurrent Epithelial Ovarian CancerLiu M, Mor G, Cheng H, Xiang X, Hui P, Rutherford T, Yin G, Rimm DL, Holmberg J, Alvero A, Silasi DA. High Frequency of Putative Ovarian Cancer Stem Cells With CD44/CK19 Coexpression Is Associated With Decreased Progression-Free Intervals In Patients With Recurrent Epithelial Ovarian Cancer. Reproductive Sciences 2013, 20: 605-615. PMID: 23171677, PMCID: PMC3635069, DOI: 10.1177/1933719112461183.
Cancerous ‘floater’: a lesson learned about tissue identity testing, endometrial cancer and microsatellite instabilityBossuyt V, Buza N, Ngo NT, Much MA, Asis MC, Schwartz PE, Hui P. Cancerous ‘floater’: a lesson learned about tissue identity testing, endometrial cancer and microsatellite instability. Modern Pathology 2013, 26: 1264-1269. PMID: 23558568, DOI: 10.1038/modpathol.2013.63.
Identification of EGFR mutation, KRAS mutation, and ALK gene rearrangement in cytological specimens of primary and metastatic lung adenocarcinomaCai G, Wong R, Chhieng D, Levy GH, Gettinger SN, Herbst RS, Puchalski JT, Homer RJ, Hui P. Identification of EGFR mutation, KRAS mutation, and ALK gene rearrangement in cytological specimens of primary and metastatic lung adenocarcinoma. Cancer Cytopathology 2013, 121: 500-507. PMID: 23495083, DOI: 10.1002/cncy.21288.
Deparaffinization and Lysis by Hydrothermal Pressure (Pressure Cooking) Coupled With Chaotropic Salt Column PurificationZhong H, Liu Y, Talmor M, Wu B, Hui P. Deparaffinization and Lysis by Hydrothermal Pressure (Pressure Cooking) Coupled With Chaotropic Salt Column Purification. Applied Immunohistochemistry & Molecular Morphology 2013, 22: 52-58. PMID: 23370427, DOI: 10.1097/pdm.0b013e318263f092.
Landscape of somatic single-nucleotide and copy-number mutations in uterine serous carcinomaZhao S, Choi M, Overton JD, Bellone S, Roque DM, Cocco E, Guzzo F, English DP, Varughese J, Gasparrini S, Bortolomai I, Buza N, Hui P, Abu-Khalaf M, Ravaggi A, Bignotti E, Bandiera E, Romani C, Todeschini P, Tassi R, Zanotti L, Carrara L, Pecorelli S, Silasi DA, Ratner E, Azodi M, Schwartz PE, Rutherford TJ, Stiegler AL, Mane S, Boggon TJ, Schlessinger J, Lifton RP, Santin AD. Landscape of somatic single-nucleotide and copy-number mutations in uterine serous carcinoma. Proceedings Of The National Academy Of Sciences Of The United States Of America 2013, 110: 2916-2921. PMID: 23359684, PMCID: PMC3581983, DOI: 10.1073/pnas.1222577110.
Composite Peripheral T-cell Lymphoma Not Otherwise Specified, and B-cell Small Lymphocytic Lymphoma Presenting With Hemophagocytic LymphohistiocytosisAlomari A, Hui P, Xu M. Composite Peripheral T-cell Lymphoma Not Otherwise Specified, and B-cell Small Lymphocytic Lymphoma Presenting With Hemophagocytic Lymphohistiocytosis. International Journal Of Surgical Pathology 2012, 21: 303-308. PMID: 23129836, DOI: 10.1177/1066896912464047.
[Genetic basis of molar pregnancy].Hui P, Liu Y. [Genetic basis of molar pregnancy]. 中华病理学杂志 2012, 41: 721-4. PMID: 23302329, DOI: 10.3760/cma.j.issn.0529-5807.2012.11.001.
Molecular pathology as the driving force for personalized oncology.Oktay MH, Hui P. Molecular pathology as the driving force for personalized oncology. Expert Review Of Molecular Diagnostics 2012, 12: 811-3. PMID: 23249199, DOI: 10.1586/erm.12.121.
Relapsing and Remitting Severe Hypoglycemia due to a Monoclonal Anti-insulin Antibody Heralding a Case of Multiple MyelomaWaldron-Lynch F, Inzucchi SE, Menard L, Tai N, Preston-Hurlburt P, Hui P, McClaskey J, Hagopian WA, Meffre E, Marks PW, Wen L, Herold KC. Relapsing and Remitting Severe Hypoglycemia due to a Monoclonal Anti-insulin Antibody Heralding a Case of Multiple Myeloma. The Journal Of Clinical Endocrinology & Metabolism 2012, 97: 4317-4323. PMID: 23074233, PMCID: PMC3513536, DOI: 10.1210/jc.2012-2388.
BRAF V600E mutation in papillary thyroid microcarcinoma: a genotype–phenotype correlationVirk RK, Van Dyke AL, Finkelstein A, Prasad A, Gibson J, Hui P, Theoharis CG, Carling T, Roman SA, Sosa JA, Udelsman R, Prasad ML. BRAF V600E mutation in papillary thyroid microcarcinoma: a genotype–phenotype correlation. Modern Pathology 2012, 26: 62-70. PMID: 22918165, DOI: 10.1038/modpathol.2012.152.
Comparing Two Methods of Detection for Chlamydia trachomatis in Liquid-Based Papanicolaou TestsLevi AW, Beckman D, Hui P, Schofield K, Harigopal M, Chhieng DC. Comparing Two Methods of Detection for Chlamydia trachomatis in Liquid-Based Papanicolaou Tests. American Journal Of Clinical Pathology 2012, 138: 236-240. PMID: 22904135, DOI: 10.1309/ajcp2b7xqtcnamjp.
Molecular Diagnostics in the Evaluation of Thyroid SamplesTheoharis C, Hui P. Molecular Diagnostics in the Evaluation of Thyroid Samples. 2012, 107-119. DOI: 10.1007/978-3-642-23459-0_7.
Corrigendum to “The Significance of Perineural Invasion in Early-stage Cervical Cancer” [Gynecologic Oncology 123 (2011) 561–564]ElSahwi K, Barber E, Illuzzi J, Buza N, Ratner E, Silasi D, Santin A, Azodi M, Schwartz P, Hui P, Rutherford T. Corrigendum to “The Significance of Perineural Invasion in Early-stage Cervical Cancer” [Gynecologic Oncology 123 (2011) 561–564]. Gynecologic Oncology 2012, 125: 770. DOI: 10.1016/j.ygyno.2012.02.026.
Next Generation Sequencing: Chemistry, Technology and ApplicationsHui P. Next Generation Sequencing: Chemistry, Technology and Applications. 2012, 336: 1-18. PMID: 22648865, DOI: 10.1007/128_2012_329.
Demographics of uterine serous cancer (USC) patients: A single institutional experience.de Leon M, Lu L, Hui P, Santin A, Rutherford T, Arin-Silasi D, Azodi M, Ratner E, Schwartz P. Demographics of uterine serous cancer (USC) patients: A single institutional experience. Journal Of Clinical Oncology 2012, 30: e15581-e15581. DOI: 10.1200/jco.2012.30.15_suppl.e15581.
Prognostic factors and treatment-related outcomes in patients with uterine serous cancer (USC).deLeon M, Lu L, Hui P, Santin A, Rutherford T, Arin-Silasi D, Azodi M, Ratner E, Schwartz P. Prognostic factors and treatment-related outcomes in patients with uterine serous cancer (USC). Journal Of Clinical Oncology 2012, 30: 5099-5099. DOI: 10.1200/jco.2012.30.15_suppl.5099.
New diagnostic modalities in the histopathological diagnosis of hydatidiform molesBuza N, Hui P. New diagnostic modalities in the histopathological diagnosis of hydatidiform moles. Diagnostic Histopathology 2012, 18: 201-209. DOI: 10.1016/j.mpdhp.2012.02.004.
HER2/neu as a Potential Target for Immunotherapy in Gynecologic CarcinosarcomasGuzzo F, Bellone S, Buza N, Hui P, Carrara L, Varughese J, Cocco E, Betti M, Todeschini P, Gasparrini S, Schwartz PE, Rutherford TJ, Angioli R, Pecorelli S, Santin AD. HER2/neu as a Potential Target for Immunotherapy in Gynecologic Carcinosarcomas. International Journal Of Gynecological Pathology 2012, 31: 211-221. PMID: 22498937, PMCID: PMC3366047, DOI: 10.1097/pgp.0b013e31823bb24d.
BRAF mutation testing in clinical practiceZiai J, Hui P. BRAF mutation testing in clinical practice. Expert Review Of Molecular Diagnostics 2012, 12: 127-138. PMID: 22369373, DOI: 10.1586/erm.12.1.
Diagnostic value of K‐ras mutation analysis for pancreaticobiliary cytology specimens with indeterminate diagnosisCai G, Mahooti S, Lipata FM, Chhieng D, Hui P. Diagnostic value of K‐ras mutation analysis for pancreaticobiliary cytology specimens with indeterminate diagnosis. Cancer Cytopathology 2012, 120: 313-318. PMID: 22367918, DOI: 10.1002/cncy.21188.
Papillary thyroid carcinomas with and without BRAF V600E mutations are morphologically distinctFinkelstein A, Levy GH, Hui P, Prasad A, Virk R, Chhieng DC, Carling T, Roman SA, Sosa JA, Udelsman R, Theoharis CG, Prasad ML. Papillary thyroid carcinomas with and without BRAF V600E mutations are morphologically distinct. Histopathology 2012, 60: 1052-1059. PMID: 22335197, DOI: 10.1111/j.1365-2559.2011.04149.x.
BRAF Mutation Testing of Thyroid Fine-Needle Aspiration Specimens Enhances the Predictability of Malignancy in Thyroid Follicular Lesions of Undetermined SignificanceAdeniran AJ, Hui P, Chhieng DC, Prasad ML, Schofield K, Theoharis C. BRAF Mutation Testing of Thyroid Fine-Needle Aspiration Specimens Enhances the Predictability of Malignancy in Thyroid Follicular Lesions of Undetermined Significance. Acta Cytologica 2011, 55: 570-575. PMID: 22156468, DOI: 10.1159/000333274.
Persistent Trophoblastic NeoplasiaHui P. Persistent Trophoblastic Neoplasia. 2011, 139-145. DOI: 10.1007/978-1-61779-394-3_9.
Genetic Basis of Gestational Trophoblastic DiseaseHui P. Genetic Basis of Gestational Trophoblastic Disease. 2011, 41-55. DOI: 10.1007/978-1-61779-394-3_3.
Gestational Trophoblastic Disease: General AspectsHui P. Gestational Trophoblastic Disease: General Aspects. 2011, 1-14. DOI: 10.1007/978-1-61779-394-3_1.
Complete Hydatidiform MoleHui P. Complete Hydatidiform Mole. 2011, 57-75. DOI: 10.1007/978-1-61779-394-3_4.
Developmental Biology of the PlacentaHui P. Developmental Biology of the Placenta. 2011, 15-39. DOI: 10.1007/978-1-61779-394-3_2.
Molecular Diagnosis of Gestational Trophoblastic DiseaseHui P. Molecular Diagnosis of Gestational Trophoblastic Disease. 2011, 161-178. DOI: 10.1007/978-1-61779-394-3_11.
Placental Site Trophoblastic TumorHui P. Placental Site Trophoblastic Tumor. 2011, 91-103. DOI: 10.1007/978-1-61779-394-3_6.
Tumor-Like Trophoblastic ConditionsHui P. Tumor-Like Trophoblastic Conditions. 2011, 147-159. DOI: 10.1007/978-1-61779-394-3_10.
Gestational ChoriocarcinomaHui P. Gestational Choriocarcinoma. 2011, 127-137. DOI: 10.1007/978-1-61779-394-3_8.
Clear Cell Cancer of the Uterine Corpus: The Association of Clinicopathologic Parameters and Treatment on Disease ProgressionVarughese J, Hui P, Lu L, Yu H, Schwartz PE. Clear Cell Cancer of the Uterine Corpus: The Association of Clinicopathologic Parameters and Treatment on Disease Progression. Journal Of Oncology 2011, 2011: 628084. PMID: 22187554, PMCID: PMC3236522, DOI: 10.1155/2011/628084.
Her2/neu extracellular domain shedding in uterine serous carcinoma: implications for immunotherapy with trastuzumabTodeschini P, Cocco E, Bellone S, Varughese J, Lin K, Carrara L, Guzzo F, Buza N, Hui P, Silasi DA, Ratner E, Azodi M, Schwartz PE, Rutherford TJ, Pecorelli S, Santin AD. Her2/neu extracellular domain shedding in uterine serous carcinoma: implications for immunotherapy with trastuzumab. British Journal Of Cancer 2011, 105: 1176-1182. PMID: 21915118, PMCID: PMC3208497, DOI: 10.1038/bjc.2011.369.
Urinary hCG Screening in the Gynecologic Oncology PopulationRichter C, Buza N, Hui P, Silasi D, Azodi M, Santin A, Rutherford T, Schwartz P. Urinary hCG Screening in the Gynecologic Oncology Population. Journal Of Gynecologic Surgery 2011, 27: 143-146. DOI: 10.1089/gyn.2010.0048.
Prevalence of Epithelial Ovarian Cancer Stem Cells Correlates with Recurrence in Early-Stage Ovarian CancerSteffensen KD, Alvero AB, Yang Y, Waldstrøm M, Hui P, Holmberg JC, Silasi DA, Jakobsen A, Rutherford T, Mor G. Prevalence of Epithelial Ovarian Cancer Stem Cells Correlates with Recurrence in Early-Stage Ovarian Cancer. Journal Of Oncology 2011, 2011: 620523. PMID: 21904548, PMCID: PMC3166719, DOI: 10.1155/2011/620523.
Use of high‐risk human papillomavirus testing in patients with low‐grade squamous intraepithelial lesionsLevi AW, Harigopal M, Hui P, Schofield K, Chhieng DC. Use of high‐risk human papillomavirus testing in patients with low‐grade squamous intraepithelial lesions. Cancer Cytopathology 2011, 119: 228-234. PMID: 21732551, DOI: 10.1002/cncy.20172.
Reflex BRAF Testing in Thyroid Fine-Needle Aspiration Biopsy with Equivocal and Positive Interpretation: A Prospective StudyAdeniran AJ, Theoharis C, Hui P, Prasad ML, Hammers L, Carling T, Udelsman R, Chhieng DC. Reflex BRAF Testing in Thyroid Fine-Needle Aspiration Biopsy with Equivocal and Positive Interpretation: A Prospective Study. Thyroid 2011, 21: 717-723. PMID: 21568726, DOI: 10.1089/thy.2011.0021.
Minimal Uterine Serous Carcinoma With Extrauterine SpreadFlynn C, Hui P. Minimal Uterine Serous Carcinoma With Extrauterine Spread. AJSP Review And Reports 2011, 16: 104-107. DOI: 10.1097/pcr.0b013e31821734fe.
Comparison of Affirm VPIII and Papanicolaou Tests in the Detection of Infectious VaginitisLevi AW, Harigopal M, Hui P, Schofield K, Chhieng DC. Comparison of Affirm VPIII and Papanicolaou Tests in the Detection of Infectious Vaginitis. American Journal Of Clinical Pathology 2011, 135: 442-447. PMID: 21350100, DOI: 10.1309/ajcp7tbn5vzuglzu.
[Molecular diagnosis of molar pregnancy].Liu CR, Hui P. [Molecular diagnosis of molar pregnancy]. Zhonghua Bing Li Xue Za Zhi Chinese Journal Of Pathology 2011, 40: 6-10. PMID: 21429351.
Gestational trophoblastic disease: histopathological diagnosis in the molecular eraBuza N, Hui P. Gestational trophoblastic disease: histopathological diagnosis in the molecular era. Diagnostic Histopathology 2010, 16: 526-537. DOI: 10.1016/j.mpdhp.2010.08.002.
Postoperative Vaginal Cuff Brachytherapy Alone (VB) Provides Equally Effective Treatment with Less Toxicity Than External Beam Radiation and Vaginal Cuff Brachytherapy (EXT + VB) in the Treatment of Stage II Endometrial AdenocarcinomaGalper S, Harrington J, Ratner E, Deng Y, Zelterman D, Hui P, Rutherford T, Higgins S. Postoperative Vaginal Cuff Brachytherapy Alone (VB) Provides Equally Effective Treatment with Less Toxicity Than External Beam Radiation and Vaginal Cuff Brachytherapy (EXT + VB) in the Treatment of Stage II Endometrial Adenocarcinoma. International Journal Of Radiation Oncology • Biology • Physics 2010, 78: s415-s416. DOI: 10.1016/j.ijrobp.2010.07.978.
Molecular diagnosis of gestational trophoblastic diseaseHui P. Molecular diagnosis of gestational trophoblastic disease. Expert Review Of Molecular Diagnostics 2010, 10: 1023-1034. PMID: 21080819, DOI: 10.1586/erm.10.93.
Glandular Lesions of the CervixChhieng D, Hui P. Glandular Lesions of the Cervix. 2010, 59-80. DOI: 10.1007/978-1-60761-164-6_4.
Normal Histology of Female Genital OrgansChhieng D, Hui P. Normal Histology of Female Genital Organs. 2010, 1-13. DOI: 10.1007/978-1-60761-164-6_1.
Endometrial Epithelial NeoplasmsChhieng D, Hui P. Endometrial Epithelial Neoplasms. 2010, 87-105. DOI: 10.1007/978-1-60761-164-6_6.
Tumors of PeritoneumChhieng D, Hui P. Tumors of Peritoneum. 2010, 193-207. DOI: 10.1007/978-1-60761-164-6_12.
Tumors of Fallopian Tube and Broad LigamentChhieng D, Hui P. Tumors of Fallopian Tube and Broad Ligament. 2010, 139-143. DOI: 10.1007/978-1-60761-164-6_9.
Gestational Trophoblastic DiseaseChhieng D, Hui P. Gestational Trophoblastic Disease. 2010, 131-138. DOI: 10.1007/978-1-60761-164-6_8.
Lesions of the Vulva and VaginaChhieng D, Hui P. Lesions of the Vulva and Vagina. 2010, 15-34. DOI: 10.1007/978-1-60761-164-6_2.
Nonepithelial Tumors of Uterine CorpusChhieng D, Hui P. Nonepithelial Tumors of Uterine Corpus. 2010, 107-129. DOI: 10.1007/978-1-60761-164-6_7.
Epithelial Neoplasms of OvaryChhieng D, Hui P. Epithelial Neoplasms of Ovary. 2010, 145-172. DOI: 10.1007/978-1-60761-164-6_10.
Nonepithelial Tumor of OvaryChhieng D, Hui P. Nonepithelial Tumor of Ovary. 2010, 173-191. DOI: 10.1007/978-1-60761-164-6_11.
Human Papillomavirus for Cervical PathologyChhieng D, Hui P. Human Papillomavirus for Cervical Pathology. 2010, 81-85. DOI: 10.1007/978-1-60761-164-6_5.
Squamous Lesions of the CervixChhieng D, Hui P. Squamous Lesions of the Cervix. 2010, 35-58. DOI: 10.1007/978-1-60761-164-6_3.
Expression of glypican 3 in placental site trophoblastic tumorOu-Yang RJ, Hui P, Yang XJ, Zynger DL. Expression of glypican 3 in placental site trophoblastic tumor. Diagnostic Pathology 2010, 5: 64. PMID: 20868507, PMCID: PMC2954974, DOI: 10.1186/1746-1596-5-64.
A KRAS-Variant in Ovarian Cancer Acts as a Genetic Marker of Cancer RiskRatner E, Lu L, Boeke M, Barnett R, Nallur S, Chin LJ, Pelletier C, Blitzblau R, Tassi R, Paranjape T, Hui P, Godwin AK, Yu H, Risch H, Rutherford T, Schwartz P, Santin A, Matloff E, Zelterman D, Slack FJ, Weidhaas JB. A KRAS-Variant in Ovarian Cancer Acts as a Genetic Marker of Cancer Risk. Cancer Research 2010, 70: 6509-6515. PMID: 20647319, PMCID: PMC2923587, DOI: 10.1158/0008-5472.can-10-0689.
Glial Heterotopia of the Uterine Cervix: DNA Genotyping Confirmation of its Fetal OriginSiddon A, Hui P. Glial Heterotopia of the Uterine Cervix: DNA Genotyping Confirmation of its Fetal Origin. International Journal Of Gynecological Pathology 2010, 29: 394-397. PMID: 20567155, DOI: 10.1097/pgp.0b013e3181c5a7e8.
MicroRNA signatures differentiate uterine cancer tumor subtypesRatner ES, Tuck D, Richter C, Nallur S, Patel RM, Schultz V, Hui P, Schwartz PE, Rutherford TJ, Weidhaas JB. MicroRNA signatures differentiate uterine cancer tumor subtypes. Gynecologic Oncology 2010, 118: 251-257. PMID: 20542546, PMCID: PMC2918705, DOI: 10.1016/j.ygyno.2010.05.010.
HER-2/NEU overexpression in vulvar Paget disease: the Yale experienceRichter CE, Hui P, Buza N, Silasi DA, Azodi M, Santin AD, Schwartz PE, Rutherford TJ. HER-2/NEU overexpression in vulvar Paget disease: the Yale experience. Journal Of Clinical Pathology 2010, 63: 544. PMID: 20418225, DOI: 10.1136/jcp.2010.077446.
Clear Cell Adenocarcinoma of the Colon Arising in the Background of Endometriosis: A Case Report and Diagnostic ApproachFinkelstein A, Levy G, Hui P. Clear Cell Adenocarcinoma of the Colon Arising in the Background of Endometriosis: A Case Report and Diagnostic Approach. Lab Medicine 2010, 41: 111-114. DOI: 10.1309/lmjctyeh9s22vqxw.
Minimal Uterine Serous Carcinoma With Extrauterine Tumor of Identical Morphology: An Immunohistochemical Study of 13 CasesYan Z, Hui P. Minimal Uterine Serous Carcinoma With Extrauterine Tumor of Identical Morphology: An Immunohistochemical Study of 13 Cases. Applied Immunohistochemistry & Molecular Morphology 2010, 18: 75-79. PMID: 19956063, DOI: 10.1097/pai.0b013e3181b1d10e.
Overexpression of EpCAM in Uterine Serous Papillary Carcinoma: Implications for EpCAM-Specific Immunotherapy With Human Monoclonal Antibody Adecatumumab (MT201)El-Sahwi K, Bellone S, Cocco E, Casagrande F, Bellone M, Abu-Khalaf M, Buza N, Tavassoli FA, Hui P, Rüttinger D, Silasi DA, Azodi M, Schwartz PE, Rutherford TJ, Pecorelli S, Santin AD. Overexpression of EpCAM in Uterine Serous Papillary Carcinoma: Implications for EpCAM-Specific Immunotherapy With Human Monoclonal Antibody Adecatumumab (MT201). Molecular Cancer Therapeutics 2010, 9: 57-66. PMID: 20053761, PMCID: PMC2806489, DOI: 10.1158/1535-7163.mct-09-0675.
HER‐2/neu receptor gene status in endometrial carcinomas: a tissue microarray studyXu M, Schwartz P, Rutherford T, Azodi M, Santin A, Silasi D, Martel M, Hui P. HER‐2/neu receptor gene status in endometrial carcinomas: a tissue microarray study. Histopathology 2009, 56: 269-273. PMID: 20102407, DOI: 10.1111/j.1365-2559.2009.03464.x.
In vitro activity of pertuzumab in combination with trastuzumab in uterine serous papillary adenocarcinomaEl-Sahwi K, Bellone S, Cocco E, Cargnelutti M, Casagrande F, Bellone M, Abu-Khalaf M, Buza N, Tavassoli FA, Hui P, Silasi DA, Azodi M, Schwartz PE, Rutherford TJ, Pecorelli S, Santin AD. In vitro activity of pertuzumab in combination with trastuzumab in uterine serous papillary adenocarcinoma. British Journal Of Cancer 2009, 102: 134-143. PMID: 19920829, PMCID: PMC2813756, DOI: 10.1038/sj.bjc.6605448.
Anaplastic oligoastrocytoma in Turcot syndromeBaehring J, Hui P, Piepmeier J, Bannykh SI. Anaplastic oligoastrocytoma in Turcot syndrome. Journal Of Neuro-Oncology 2009, 95: 293-298. PMID: 19495563, DOI: 10.1007/s11060-009-9928-y.
Expression of Hepatocyte Antigen in Small Intestinal Epithelium and AdenocarcinomaMac MT, Chung F, Lin F, Hui P, Balzer BL, Wang HL. Expression of Hepatocyte Antigen in Small Intestinal Epithelium and Adenocarcinoma. American Journal Of Clinical Pathology 2009, 132: 80-85. PMID: 19864237, DOI: 10.1309/ajcpud0p5nqboypk.
Absence of human herpesvirus 8 in pemphigus and bullous pemphigoid.Galan A, Hui P, McNiff JM. Absence of human herpesvirus 8 in pemphigus and bullous pemphigoid. International Journal Of Clinical And Experimental Pathology 2009, 2: 456-62. PMID: 19294004, PMCID: PMC2655157.
SarcomasTallini G, Hui P. Sarcomas. 2009, 119-130. DOI: 10.1007/978-0-387-87366-4_12.
Lack of Genetic Association Between Exaggerated Placental Site Reaction and Placental Site Trophoblastic TumorJorge D, Hui P. Lack of Genetic Association Between Exaggerated Placental Site Reaction and Placental Site Trophoblastic Tumor. International Journal Of Gynecological Pathology 2008, 27: 562-567. PMID: 18753963, DOI: 10.1097/pgp.0b013e31816d1d00.
Epithelioid trophoblastic tumor: comparative genomic hybridization and diagnostic DNA genotypingXu ML, Yang B, Carcangiu ML, Hui P. Epithelioid trophoblastic tumor: comparative genomic hybridization and diagnostic DNA genotyping. Modern Pathology 2008, 22: 232-238. PMID: 18820674, DOI: 10.1038/modpathol.2008.165.
High grade cervical intraepithelial neoplasia and viral load of high-risk human papillomavirus: significant correlations in patients of 22 years old or younger.Xu Y, Dotto J, Hui Y, Lawton K, Schofield K, Hui P. High grade cervical intraepithelial neoplasia and viral load of high-risk human papillomavirus: significant correlations in patients of 22 years old or younger. International Journal Of Clinical And Experimental Pathology 2008, 2: 169-75. PMID: 19079652, PMCID: PMC2583634.
Expression of CD56 and WT1 in Ovarian Stroma and Ovarian Stromal TumorsHe H, Luthringer DJ, Hui P, Lau SK, Weiss LM, Chu PG. Expression of CD56 and WT1 in Ovarian Stroma and Ovarian Stromal Tumors. The American Journal Of Surgical Pathology 2008, 32: 884-890. PMID: 18425046, DOI: 10.1097/pas.0b013e3181609d59.
Genotypic Analysis of Hydatidiform Mole: An Accurate and Practical Method of DiagnosisBifulco C, Johnson C, Hao L, Kermalli H, Bell S, Hui P. Genotypic Analysis of Hydatidiform Mole: An Accurate and Practical Method of Diagnosis. The American Journal Of Surgical Pathology 2008, 32: 445-451. PMID: 18300805, DOI: 10.1097/pas.0b013e3181520034.
Synovial Sarcoma of the StomachMakhlouf HR, Ahrens W, Agarwal B, Dow N, Marshalleck JJ, Lee EL, Dotto JE, Hui P, Sobin LH, Oliveira A, Miettinen M. Synovial Sarcoma of the Stomach. The American Journal Of Surgical Pathology 2008, 32: 275-281. PMID: 18223331, DOI: 10.1097/pas.0b013e31812e6a58.
Pulmonary atresia with intact ventricular septum (PA‐IVS) in monozygotic twinsDe Stefano D, Li P, Xiang B, Hui P, Zambrano E. Pulmonary atresia with intact ventricular septum (PA‐IVS) in monozygotic twins. American Journal Of Medical Genetics Part A 2008, 146A: 525-528. PMID: 18203206, DOI: 10.1002/ajmg.a.32160.
Primary or Secondary? Genotyping Confirmation of an Ovarian Primary Carcinoid TumorDotto J, Mezzetti T, Hui P. Primary or Secondary? Genotyping Confirmation of an Ovarian Primary Carcinoid Tumor. International Journal Of Gynecological Pathology 2008, 27: 33-36. PMID: 18156971, DOI: 10.1097/pgp.0b13e318053df4.
Expression of Mucins, SIMA, Villin, and CDX2 in Small-Intestinal AdenocarcinomaZhang MQ, Lin F, Hui P, Chen ZM, Ritter JH, Wang HL. Expression of Mucins, SIMA, Villin, and CDX2 in Small-Intestinal Adenocarcinoma. American Journal Of Clinical Pathology 2007, 128: 808-816. PMID: 17951204, DOI: 10.1309/jaf3kvgjhqcj1qf9.
CSF IgH gene rearrangement analysis in isolated post-transplant lymphoproliferative disorder of the central nervous systemBaehring JM, Landry ML, Cooper D, Hui P, Bannykh S. CSF IgH gene rearrangement analysis in isolated post-transplant lymphoproliferative disorder of the central nervous system. Journal Of Neuro-Oncology 2007, 86: 57-60. PMID: 17909942, DOI: 10.1007/s11060-007-9429-9.
Absence of Y chromosome in human placental site trophoblastic tumorHui P, Wang HL, Chu P, Yang B, Huang J, Baergen RN, Sklar J, Yang XJ, Soslow RA. Absence of Y chromosome in human placental site trophoblastic tumor. Modern Pathology 2007, 20: 1055-1060. PMID: 17643092, DOI: 10.1038/modpathol.3800941.
SarcomasTallini G, Hui P. Sarcomas. 2007, 287-297. DOI: 10.1007/978-0-387-33227-7_26.
[Pathogenesis of endometrial cancer: clinicopathologic implications].Hui P. [Pathogenesis of endometrial cancer: clinicopathologic implications]. Zhonghua Bing Li Xue Za Zhi Chinese Journal Of Pathology 2006, 35: 705-7. PMID: 17374250.
Improved Survival in Surgical Stage I Patients With Uterine Papillary Serous Carcinoma (UPSC) Treated With Adjuvant Platinum-Based ChemotherapyKelly M, O’Malley D, Hui P, McAlpine J, Yu H, Rutherford T, Azodi M, Schwartz P. Improved Survival in Surgical Stage I Patients With Uterine Papillary Serous Carcinoma (UPSC) Treated With Adjuvant Platinum-Based Chemotherapy. Obstetrical & Gynecological Survey 2006, 61: 27-29. DOI: 10.1097/01.ogx.0000193850.73725.34.
Benign metastasizing leiomyoma: clonality, telomere length and clinicopathologic analysisPatton KT, Cheng L, Papavero V, Blum MG, Yeldandi AV, Adley BP, Luan C, Diaz LK, Hui P, Yang XJ. Benign metastasizing leiomyoma: clonality, telomere length and clinicopathologic analysis. Modern Pathology 2006, 19: 130-140. PMID: 16357844, DOI: 10.1038/modpathol.3800504.
HMGA proteins in malignant peripheral nerve sheath tumor and synovial sarcoma: preferential expression of HMGA2 in malignant peripheral nerve sheath tumorHui P, Li N, Johnson C, De Wever I, Sciot R, Manfioletti G, Tallini G. HMGA proteins in malignant peripheral nerve sheath tumor and synovial sarcoma: preferential expression of HMGA2 in malignant peripheral nerve sheath tumor. Modern Pathology 2005, 18: 1519-1526. PMID: 16056249, DOI: 10.1038/modpathol.3800464.
Recurrent endometrial stromal tumors with smooth-muscle differentiation and a protracted clinical courseHui P, Fedoriw G. Recurrent endometrial stromal tumors with smooth-muscle differentiation and a protracted clinical course. Nature Reviews Clinical Oncology 2005, 2: 588-593. PMID: 16270099, DOI: 10.1038/ncponc0340.
BRAF mutation predicts a poorer clinical prognosis for papillary thyroid cancer.Xing M, Westra WH, Tufano RP, Cohen Y, Rosenbaum E, Rhoden KJ, Carson KA, Vasko V, Larin A, Tallini G, Tolaney S, Holt EH, Hui P, Umbricht CB, Basaria S, Ewertz M, Tufaro AP, Califano JA, Ringel MD, Zeiger MA, Sidransky D, Ladenson PW. BRAF mutation predicts a poorer clinical prognosis for papillary thyroid cancer. The Journal Of Clinical Endocrinology & Metabolism 2005, 90: 6373-9. PMID: 16174717, DOI: 10.1210/jc.2005-0987.
Improved survival in surgical stage I patients with uterine papillary serous carcinoma (UPSC) treated with adjuvant platinum-based chemotherapyKelly MG, O'Malley DM, Hui P, McAlpine J, Yu H, Rutherford TJ, Azodi M, Schwartz PE. Improved survival in surgical stage I patients with uterine papillary serous carcinoma (UPSC) treated with adjuvant platinum-based chemotherapy. Gynecologic Oncology 2005, 98: 353-359. PMID: 16005947, DOI: 10.1016/j.ygyno.2005.06.012.
Identification of Binding Sites of EVI1 in Mammalian Cells*Yatsula B, Lin S, Read AJ, Poholek A, Yates K, Yue D, Hui P, Perkins AS. Identification of Binding Sites of EVI1 in Mammalian Cells*. Journal Of Biological Chemistry 2005, 280: 30712-30722. PMID: 16006653, DOI: 10.1074/jbc.m504293200.
Improved survival in surgical stage I uterine papillary serous cancer (UPSC) treated with adjuvant platinum-based chemoradiationKelly M, O’Malley D, Hui P, Dziura J, McAlpine J, Azodi M, Rutherford T, Schwartz P. Improved survival in surgical stage I uterine papillary serous cancer (UPSC) treated with adjuvant platinum-based chemoradiation. Journal Of Clinical Oncology 2005, 23: 5023-5023. DOI: 10.1200/jco.2005.23.16_suppl.5023.
Atypical angiomyolipoma of kidney in a patient with tuberous sclerosis: a case report with p53 gene mutation analysis.Ma L, Kowalski D, Javed K, Hui P. Atypical angiomyolipoma of kidney in a patient with tuberous sclerosis: a case report with p53 gene mutation analysis. Archives Of Pathology & Laboratory Medicine 2005, 129: 676-9. PMID: 15859641, DOI: 10.5858/2005-129-0676-aaokia.
Minimal uterine serous carcinoma: a clinicopathological study of 40 casesHui P, Kelly M, O'Malley DM, Tavassoli F, Schwartz PE. Minimal uterine serous carcinoma: a clinicopathological study of 40 cases. Modern Pathology 2005, 18: 75-82. PMID: 15389257, DOI: 10.1038/modpathol.3800271.
Patients with uterine papillary serous cancers may benefit from adjuvant platinum-based chemoradiationKelly MG, O'Malley D, Hui P, McAlpine J, Dziura J, Rutherford TJ, Azodi M, Chambers SK, Schwartz PE. Patients with uterine papillary serous cancers may benefit from adjuvant platinum-based chemoradiation. Gynecologic Oncology 2004, 95: 469-473. PMID: 15581948, DOI: 10.1016/j.ygyno.2004.08.030.
Human herpesvirus‐8 is not associated with angiolymphoid hyperplasia with eosinophiliaBhattacharjee P, Hui P, McNiff J. Human herpesvirus‐8 is not associated with angiolymphoid hyperplasia with eosinophilia. Journal Of Cutaneous Pathology 2004, 31: 612-615. PMID: 15330993, DOI: 10.1111/j.0303-6987.2004.00240.x.
Differential Expression of HMGA1 and HMGA2 in Dermatofibroma and Dermatofibrosarcoma Protuberans: Potential Diagnostic Applications, and Comparison with Histologic Findings, CD34, and Factor XIIIa ImmunoreactivityLi N, McNiff J, Hui P, Manfioletti G, Tallini G. Differential Expression of HMGA1 and HMGA2 in Dermatofibroma and Dermatofibrosarcoma Protuberans: Potential Diagnostic Applications, and Comparison with Histologic Findings, CD34, and Factor XIIIa Immunoreactivity. American Journal Of Dermatopathology 2004, 26: 267-272. PMID: 15249855, DOI: 10.1097/00000372-200408000-00001.
STAT3-Mediated Signaling in the Determination of Rod Photoreceptor Cell Fate in Mouse RetinaZhang SS, Wei J, Qin H, Zhang L, Xie B, Hui P, Deisseroth A, Barnstable CJ, Fu XY. STAT3-Mediated Signaling in the Determination of Rod Photoreceptor Cell Fate in Mouse Retina. Investigative Ophthalmology & Visual Science 2004, 45: 2407-2412. PMID: 15223824, DOI: 10.1167/iovs.04-0003.
Comparative genomic hybridization study of placental site trophoblastic tumour: a report of four casesHui P, Riba A, Pejovic T, Johnson T, Baergen RN, Ward D. Comparative genomic hybridization study of placental site trophoblastic tumour: a report of four cases. Modern Pathology 2004, 17: 248-251. PMID: 14657956, DOI: 10.1038/modpathol.3800025.
Real-time Quantitative RT-PCR of Cyclin D1 mRNA in Mantle Cell Lymphoma: Comparison with FISH and ImmunohistochemistryHui* P, Howe* J, Crouch J, Nimmakayalu M, Qumsiyeh MB, Tallini G, Flynn SD, Smith BR. Real-time Quantitative RT-PCR of Cyclin D1 mRNA in Mantle Cell Lymphoma: Comparison with FISH and Immunohistochemistry. Leukemia & Lymphoma 2003, 44: 1385-1394. PMID: 12952233, DOI: 10.1080/1042819031000079168.
Clonal analysis of cutaneous fibrous histiocytoma (dermatofibroma)Hui P, Glusac EJ, Sinard JH, Perkins AS. Clonal analysis of cutaneous fibrous histiocytoma (dermatofibroma). Journal Of Cutaneous Pathology 2002, 29: 385-389. PMID: 12139632, DOI: 10.1034/j.1600-0560.2002.290701.x.
Assessment of RET/PTC Oncogene Activation and Clonality in Thyroid Nodules with Incomplete Morphological Evidence of Papillary Carcinoma A Search for the Early Precursors of Papillary CancerFusco A, Chiappetta G, Hui P, Garcia-Rostan G, Golden L, Kinder BK, Dillon DA, Giuliano A, Cirafici AM, Santoro M, Rosai J, Tallini G. Assessment of RET/PTC Oncogene Activation and Clonality in Thyroid Nodules with Incomplete Morphological Evidence of Papillary Carcinoma A Search for the Early Precursors of Papillary Cancer. American Journal Of Pathology 2002, 160: 2157-2167. PMID: 12057919, PMCID: PMC1850819, DOI: 10.1016/s0002-9440(10)61164-9.
Isolated Noncompaction of the Ventricular Myocardium: Clinical and Molecular Aspects of a Rare CardiomyopathyZambrano E, Marshalko SJ, Jaffe CC, Hui P. Isolated Noncompaction of the Ventricular Myocardium: Clinical and Molecular Aspects of a Rare Cardiomyopathy. Laboratory Investigation 2002, 82: 117-122. PMID: 11850525, DOI: 10.1038/labinvest.3780404.
Multiple Angiomyolipomata of the Liver: A Case ReportTang LH, Hui P, Garcia-Tsao G, Salem RR, Jain D. Multiple Angiomyolipomata of the Liver: A Case Report. Modern Pathology 2002, 15: 167-171. PMID: 11850546, DOI: 10.1038/modpathol.3880509.
Bloom Syndrome in Sibs: First Reports of Hepatocellular Carcinoma and Wilms Tumor with Documented Anaplasia and Nephrogenic RestsJain D, Hui P, McNamara J, Schwartz D, German J, Reyes-Múgica M. Bloom Syndrome in Sibs: First Reports of Hepatocellular Carcinoma and Wilms Tumor with Documented Anaplasia and Nephrogenic Rests. Pediatric And Developmental Pathology 2001, 4: 585-589. PMID: 11826367, DOI: 10.1007/s10024001-0082-6.
Bloom Syndrome in Sibs: First Reports of Hepatocellular Carcinoma and Wilms Tumor with Documented Anaplasia and Nephrogenic RestsJain D, Hui P, McNamara J, Schwartz D, German J, Reyes-Múgica M. Bloom Syndrome in Sibs: First Reports of Hepatocellular Carcinoma and Wilms Tumor with Documented Anaplasia and Nephrogenic Rests. Pediatric And Developmental Pathology 2001, 4: 585-589. DOI: 10.1007/s10024-001-0082-6.
Assessment of clonality in melanocytic neviHui P, Perkins A, Glusac E. Assessment of clonality in melanocytic nevi. Journal Of Cutaneous Pathology 2001, 28: 140-144. PMID: 11168766, DOI: 10.1034/j.1600-0560.2001.028003140.x.
Identification of candidate target genes for EVI-1, a zinc finger oncoprotein, using a novel selection strategyKim J, Hui P, Yue D, Aycock J, Leclerc C, Bjoring A, Perkins A. Identification of candidate target genes for EVI-1, a zinc finger oncoprotein, using a novel selection strategy. Oncogene 1998, 17: 1527-1538. PMID: 9794230, DOI: 10.1038/sj.onc.1202331.

Clinical Trials

Conditions	Study Title
Corpus Uteri; Other Female Genital	A Phase II Evaluation of Afatinib

Edit Profile

Contact Information

Office Location

Related Links

Patient Care

Research & Publications

Biography

News

Locations